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1. SUMMARY 
 
Amino acids play a pivotal role in every living organism as they function as 
building blocks of proteins, signaling molecules, metabolic precursor, etc. Due to 
their multiple roles in the body, amino acids availability must be tightly controlled 
and relies on their transport across cellular membrane via amino acid transporters. 
In the kidney proximal tubule and in the small intestine, the overall directional 
(re)absorptive transport of amino acids is mainly driven by accumulative 
transporters located in the apical membrane of epithelial cells. The best 
characterized luminal transporter for neutral amino acids is B0AT1 (SLC6A19). 
Expression and function of B0AT1 in the kidney have been shown to depend on the 
associated protein collectrin/TMEM27 (Danilczyk et al., 2006). To better understand 
the cellular and molecular mechanism underlying this interaction, we generated 
MDCK cells inducibly overexpressing B0AT1 and/or TMEM27. Our data showed that 
TMEM27 increases B0AT1 function by upregulating its surface expression. 
Interestingly, we found that the expression of the amino acid transporter and its 
accessory protein strongly decreased following subsequent cell culture passages. 
We tested the impact of cell culture medium amino acid concentrations on the 
transporter and found that high amino acid levels inhibit B0AT1 protein abundance. 
In contrast, the expression of a control transgene remained stable. To test whether 
this loss was due to inappropriately high amino acid uptake, freshly transduced 
MDCK cell lines were cultivated either with physiological amounts of amino acids or 
with the high concentration found in standard cell culture media. Expression of 
exogenous transporters was unaffected by physiological amino acid concentration in 
the media. Interestingly, mycoplasma infection resulted in a significant increase in 
transgene expression and correlated with the rapid metabolism of L-arginine. 
However, L-arginine metabolites were shown to play no role in transgene 
expression. In contrast, activation of the GCN2 pathway revealed by an increase in 
eIF2α phosphorylation may trigger transgene derepression. In addition to the 
transgene regulation, we found that mycoplasma-induced arginine depletion 
dramatically affected MDCK epithelia, resulting in a decrease in cell number and 
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trans-epithelial electrical resistance corresponding in a delay in tight junction 
formation. 
Taken together, high extracellular amino acid concentration provided by cell 
culture media appears to inhibit the constitutive expression of concentrative amino 
acid transporters whereas L-arginine depletion by mycoplasma induces the 
expression of transgenes via stimulation of the GCN2 pathway. 
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2. ZUSAMMENFASSUNG 
Aminosäuren spielen in jedem lebenden Organismus eine Schlüsselrolle, da sie 
als Bausteine für Proteine, Signalmoleküle, metabolische Vorläufermoleküle, etc. 
dienen. Aufgrund ihrer vielfachen Funktionen im Körper muss ihre Verfügbarkeit 
stark kontrolliert sein und ist vom Transport durch Zellmembrane via 
Aminosäuretransportern abhängig.  
In den proximalen Tubuli der Niere und im Dünndarm ist der gerichtete, 
(re)absorbierende Aminosäurentransport hauptsächlich durch akkumulative 
Transporter der apikalen Membran von Epithelzellen angetrieben. Der am besten 
charakterisierte luminale Transporter für neutrale Aminosäuren ist B0AT1 
(SLC6A19). Es wurde gezeigt, dass die Expression und Funktion von B0AT1 in der 
Niere vom assoziierten Protein Collectrin/TMEM27 abhängig ist (Danilczyk et al., 
2006). Um die zellulären und molekularen Mechanismen die dieser Interaktion 
zugrunde liegen genauer zu verstehen, generierten wir MDCK Zellen die 
induzierbar B0AT1 und/oder TMEM27 überexprimieren. Unsere Daten zeigten dass 
TMEM27 die B0AT1 Funktion durch Hochregulation seiner Oberflächenexpression 
steigert. Interessanterweise fanden wir heraus, dass sich die Funktion dieses 
Aminosäuretransporter und seines assoziierten Proteins sich mit steigender 
Zellkultur-Passage stark reduziert. Wir überprüften den Einfluss der 
Aminosäurekonzentrationen im Zellkulturmedium auf den Transporter und fanden 
heraus, dass ein hohes Aminosäure-Niveau zu einer Reduktion der Menge des 
Proteins B0AT1 führt. Im Gegensatz dazu blieb die Expression eines Kontroll-
Transgens stabil. Um zu überprüfen ob diese Minderung aufgrund einer 
unangemessen hohen Aufnahme von Aminosäuren zustande kam, wurden frisch 
transduzierte MDCK Zellen entweder mit physiologischen Mengen von 
Aminosäuren oder mit der hohen Konzentration, wie in Standard-Zellkulturmedium 
gefunden, kultiviert. Die Expression exogener Transporter blieb unbeeinflusst durch 
physiologische Aminosäurekonzentrationen im Medium. Interessanterweise hatte 
eine Infektion mit Mykoplasmen eine signifikant erhöhte Transgen-Expression zur 
Folge welche mit der schnellen Metabolisierung von L-Arginin korrelierte. Allerdings 
wurde gezeigt, dass Metabolite von L-Arginin keine Rolle für die Transgen-
Expression spielen. Die Aktivierung des GCN2 Stoffwechselweges, welche durch 
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eine Zunahme der Phosphorilierung des eIF2α festgestellt wuden, könnte hingegen 
die Transgen-Derepression ausgelöst haben. Zusätzlich zur Transgenregulation 
fanden wir heraus, dass der Mykoplasmen-induzierter Arginin-Mangel das MDCK 
Epithel stark beeinflusst. Es führte zum Beispiel zu einer Verminderung der Zellzahl 
und des trans-epithelialen elektrischen Widerstands, wobei Letzteres einer 
Verzögerung der Bildung von Tight-Junctions entspricht. 
Zusammenfassend konnten wir zeigen, dass eine durch das Zellkulturmedium 
bereitgestellte hohe extrazelluläre Aminosäurekonzentration die konstitutive 
Expression von Aminosäuretransportern zu inhibieren scheint, wohingegen durch 
Mykoplasmen verursachter L-Arginin-Mangel die Expression von Transgenen 
durch Stimulation des GCN2-Stoffwechselweges induziert. 
3. INTRODUCTION 
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3. INTRODUCTION 
 
3.1 Anatomy and physiology of the kidney 
The kidneys are essential organs for the body homeostasis. They function as 
filters, disposing the metabolic products and the toxins from the blood and excreting 
them through the urine. They regulate the body’s fluid volume and maintain the 
electrolyte and acid-base balance. They secrete important hormones such as 
erythropoietin, renin and calcitriol. 
The human kidneys are paired, bean-shaped and located in the retroperitoneal 
cavity. The functional unit of the kidney is the nephron (8·105 - 1.2·106 in humans) 
which consists of the glomerulus and the tubule. The glomerulus is a tuft of 
capillaries from which the plasma filtrate is formed. The tubule consists of highly 
specialized epithelial cells which are responsible for converting the filtrate into urine 
by reabsorbing fluids, electrolytes and nutrients. The tubule is subdivided into 
several segments with different sequential function: proximal convoluted tubule 
(PCT), proximal straight tubule (PST), thin descending limb of Henle’s loop (tDLH), 
thin ascending limb of Henle’s loop (tALH), thick ascending limb of Henle’s loop 
(TAL), distal convoluted tubule (DCT), connecting tubule (CNT), cortical collecting 
duct (CCD), outer and inner medullar collecting duct (OMCD and IMCD) (Fig.1).  
  
Figure 1. Organization of the nephron. The 
nephron comprises the glomerulus, which filters the 
blood, and the renal tubules, where reabsorption 
and secretion of ions and solutes occur. The tubule 
is subdivided in several segments. PT, proximal 
tubule; S1, S2 and S3, segments of the proximal 
tubule; TAL, thick ascending limbs; DCT1/2, distal 
convoluted tubule; CNT, connecting tubule; CCD, 
cortical collecting duct; OMCD, medullary collecting 
duct. Figure taken from (Makrides et al., 2014) 
3. INTRODUCTION 
 
6 
 
The proximal tubules play a pivotal role in reabsorption of most of the nutrients 
(eg., amino acids and glucose), ions (eg., Ca2+, HPO42-), water and salts (NaCl and 
NaHCO3), which all together represent the largest fraction of the glomerular filtrate.  
 
3.2 Tubular amino acid reabsorption 
Kidneys play an essential role in maintaining the body homeostasis, by tightly 
controlling the plasma levels of several nutrients which are present at low 
concentration in the body. Among those molecules, amino acids, which all together 
have a plasma concentration of ~ 2.5 mM, represent an interesting example (Verrey 
et al., 2005). Amino acids are derived from protein catabolism, de novo synthesis as 
well as intestinal absorption after a meal. Due to their small size, glomeruli are able 
to freely filter them and they would be lost in the urine if the tubular cells did not 
reabsorb them. Since amino acids are important for the human body, 98% of them 
are retrieved from the filtrate in the proximal tubules, corresponding to more than 
50 g per day. Amino acid reabsorption occurs mostly in the first half of the proximal 
convoluted tubules (segment S1), where epithelial cells are equipped with a wide 
range of amino acid transporters on both cellular membranes (Fig. 2).  
 
  
Figure 2. Schematic 
representation of the AA 
reabsorption in a renal 
proximal tubular cell. 
Amino acid transporters are 
indicated with SLC 
nomenclature and common 
names. Transported AAs are 
labeled in red.  AA0 neutral 
amino acid, AA- anionic 
amino acid, AA+ cationic, Coll 
collectrin/TMEM27. Figure 
taken from (Verrey et al., 
2009). 
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At the apical membrane, amino acids enter the cells driven by the energetically 
favorable co-transport of Na+ or H+, as well as by exchangers. The exit from the cell 
is mediated by exchangers and facilitated diffusion pathways expressed on the 
basolateral membrane.  
 
3.3 Amino acid transporters 
Due to their complex nomenclature, transporters have been classified as Solute 
Carriers (SLC) in 52 families (http://slc.bioparadigms.org) based on their sequence 
homology. Among the members of the SLC families, there are about 50 genes 
coding for amino acid transporters grouped in 11 different families. In this thesis, I 
will focus on the neutral amino acid transporter SLC6A19 or B0AT1 and its partner 
proteins TMEM27 and ACE2. 
 
3.3.1 B0AT1 (SLC6A19) 
The neutral amino acid transporter B0AT1 was first identified in 2004 in mice 
(Bröer et al., 2004), although evidences of its functional role had already been 
reported long before (Doyle and McGivan, 1992). B0AT1 belongs to the family SLC6 
of sodium- and chloride-dependent neurotransmitter transporters. It has been shown 
to localize in the brush border of the early proximal tubules (S1) and small intestine 
(Romeo et al., 2006). B0AT1 function has been investigated through 
electrophysiological experiments in Xenopus laevis oocytes, which have shown an 
electrogenic transport of a broad range of neutral amino acids (Böhmer et al., 2005; 
Camargo et al., 2005). B0AT1 has a low affinity for most of the neutral amino acids 
(Km is in the low millimolar range) and its function does not depend on the presence 
of chloride, unlike for most other members of the SLC6 family. 
Expression and function of B0AT1 has been shown to depend on the co-
expression of members of the Renin Angiotensin System (RAS), namely TMEM27 
(collectrin) or angiotensin converting enzyme (ACE2) (Danilczyk et al., 2006; 
Camargo et al., 2009). The amino acid transporter interaction with its accessory 
proteins appeared to be organ specific. In the intestine, where TMEM27 is absent, 
B0AT1 interacts with ACE2. In the kidneys although there is some expression of 
ACE2, B0AT1 specifically interacts with TMEM27. In addition to ACE2 and 
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TMEM27, a novel interacting protein has been recently discovered in the intestine. 
The aminopeptidase N/CD13 has been shown to physically interact with the amino 
acid transporter in vivo and to increase B0AT1 apparent affinity when co-expressed 
in vitro (Fairweather et al., 2012). B0AT1 specific interaction with the associated 
proteins will be discuss in details in the next sections (3.3.2 and 3.3.3). 
The human gene SLC6A19 localizes to chromosome 5p15.33 and codes for a 
634 amino acids protein. Mutations in the gene have been shown to cause an 
autosomal recessive condition, named Hartnup disorder, characterized by a neutral 
aminoaciduria (Kleta et al., 2004; Seow et al., 2004) (Fig. 3). In some cases, the 
urinary excretion of amino acids can be accompanied by pellagra-like symptoms 
including light-sensitive dermatitis, cerebellar ataxia, and other neurological or 
psychiatric symptoms (Henderson, 1958; Scriver, 1965; Bröer, 2009). Part of the 
phenotypic heterogeneity of Hartnup disorder may be due to the differential 
interactions of B0AT1 mutants with the tissue specific accessory proteins (Camargo 
et al., 2009). Data obtained from Slc6a19 null mouse confirmed an aminoaciduria 
consistent with the Hartnup disorder phenotype. The knockout eliminated both 
intestinal and renal expression of B0AT1 although neither expression nor function of 
other neutral amino acid transporters was affected. Similarly, TMEM27 and ACE2 
expression was not altered (Bröer et al., 2011). 
Figure 3. Depiction of B0AT1 and Hartnup mutations. Mutations are indicated in red; arrowheads 
indicate splice sites. Figure taken from (Kleta et al., 2004). 
 
The regulation of B0AT1 has been extensively studied in different models such 
as Xenopus laevis oocytes and renal and intestinal cell lines in vitro, as well as 
various animal models in vivo. In addition to the already mentioned accessory 
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proteins TMEM27 and ACE2, which regulate the amino acid transporter expression, 
several kinases including the serum and glucocorticoid inducible kinases SGK1-3 
(Böhmer et al., 2010), the Janus-activated kinase-2 JAK2 (Bhavsar et al., 2011), 
protein kinase B PKB/Akt and phosphatidylinositol-3 phosphate-5-kinase (PIKfyve) 
(Bogatikov et al., 2012) have been shown to upregulate B0AT1 function when co-
expressed in Xenopus laevis oocytes. Recent studies in vitro (Fanjul et al., 2012) 
and ex vivo (Ducroc et al., 2010) have suggested that leptin controls B0AT1 activity 
via regulation of the protein traffic to the plasma membrane and modulation of the 
gene expression.  
 
3.3.2 ACE2 
ACE2 or ACEH was originally discovered as a homolog of ACE (Donoghue et 
al., 2000; Tipnis et al., 2000). The ACE2 gene is mapped to the X chromosome and 
codes for an 805 amino acid type I glycoprotein. ACE2 is a zinc metallopeptidase 
oriented with the long N-terminus and catalytic site towards the extracellular space, 
where it can metabolize circulating peptides. Unlike somatic ACE, ACE2 contains 
only one active site and exhibits carboxymonopeptidase activity, cleaving a single 
C-terminal residue from peptide substrates. The carboxy-terminal domain of ACE2 
is rather shorter and faces the cytoplasmic space. Interestingly, ACE2 shares about 
42% identity with the amino-terminal domain of ACE (Donoghue et al., 2000) and 
about 48% identity with TMEM27 (Zhang et al., 2001). Therefore, ACE2 is 
considered a chimeric protein generated from the amino-terminal domain of ACE 
and carboxy-terminal domain of TMEM27 (Fig. 4). 
ACE2 is highly expressed in the kidney on the apical surface of tubular epithelial 
cells, in the heart (both in the endothelium and in the cardiomyocytes), and in the 
adult Leydig cells of the testis ACE (Donoghue et al., 2000; Tipnis et al., 2000). 
Evidences of expression in the small intestine, lung, liver and placenta have been 
also reported (Hamming et al., 2007). 
Three major ACE2 functions have been described so far (Fig. 5). The best 
known role of ACE2 is played within the RAS. While ACE cleaves angiotensin I 
(Ang I) to produce the potent vasoconstrictor angiotensin II (Ang II), ACE2 is a 
carboxypeptidase which converts angiotensin II (Ang II) to the vasodilator 
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heptapeptide angiotensin 1-7 (Ang 1-7). Therefore, ACE2 is often regarded as a 
negative regulator of ACE (Eriksson et al., 2002). In addition, ACE2 can also directly 
metabolize Ang I to generate angiotensin 1-9 (Ang 1-9) with lower efficiency than 
converting Ang II to Ang 1-7 (Corvol et al., 1995; Donoghue et al., 2000; Vickers et 
al., 2002). 
Figure 4. The domain structure of somatic ACE, ACE2 and TMEM27 (collectrin). Each protein is 
a type I integral membrane protein with a signal peptide (grey), and a transmembrane domain 
(black). The zinc-binding motif (HEMGH) repeats twice in ACE and once in ACE2, and is located 
within the homology region denoted by the yellow box. Regions of homology between ACE2 and 
TMEM27 are denoted in green, whereas homology of ACE and ACE2 is shown in blue. The numbers 
refer to the amino acids in each human protein. Figure taken from (Kuba et al., 2013). 
 
The second role of ACE2 is played as severe acute respiratory syndrome 
corona-virus (SARS-CoV) receptor. Both in vitro (Li et al., 2003) and in vivo (Kuba et 
al., 2005) studies demonstrated that ACE2 mediates SARS-CoV infection through 
binding of the SARS-spike protein to its extracellular domain. The interaction of 
SARS-CoV with ACE2 leads to the endocytosis of virus particles through 
internalization with ACE2 and results in SARS-CoV infection. Although the receptor 
function does not require the peptidase activity of ACE2, the downregulation of 
ACE2 expression by SARS-CoV infection activates the renin angiotensin system 
and could explain the severe lung injury and acute lung failure typical in SARS 
pathology (Kuba et al., 2005). The third role of ACE2 is played as amino acid 
transporter partner protein. Studies by our group (Camargo et al., 2009) and others 
(Kowalczuk et al., 2008) demonstrated ACE2 co-localization with B0AT1 at the 
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apical surface of the enterocytes in mice and human. In Ace2 null mice, B0AT1 
expression is completely abolished in the small intestine, but normal in kidney. In 
addition, the physical interaction between the amino acid transporter and ACE2 has 
been confirmed by co-immunoprecipitation experiments in vitro and in vivo 
(Camargo et al., 2009). Similarly to its role as SARS-CoV receptor, ACE2 does not 
seem to require its carboxypeptidase activity to function as amino acid transporter 
partner protein. This theory is supported by in vitro studies which have shown that a 
catalytically dead ACE2 mutant was still able to promote B0AT1 function (Camargo 
et al., 2009). Interestingly, Slc6a19 null mice have not shown any decrease in ACE2 
expression (Bröer et al., 2011). Furthermore, ACE2 is appropriately localized to 
membranes in organs in which the amino acid transporter is not expressed, 
consistent with the transporter having no impact on renin angiotensin system 
expression. In addition to B0AT1, ACE2 has been shown to interact with SIT1 
(SLC6A20) in the gut (Singer and Camargo, 2011), and B0AT3 (SLC6A18) in the 
kidney (Singer et al., 2009). Recent studies (Hashimoto et al., 2012) have shown 
that Ace2 deficient mice are more susceptible to experimentally induced colitis than 
the wild type littermates. This effect is due to an impaired amino acid absorption, 
which in turns affects the composition of the intestinal microbiota. 
Figure 5. Multiple roles of ACE2. (A) ACE2 is a carboxypeptidase which converts angiotensin II 
(Ang II) to produce the heptapeptide angiotensin 1-7 (Ang 1-7). (B) ACE2 is a SARS-CoV receptor. 
(C) ACE2 interacts with amino acid transporters. Figure modified from (Kuba et al., 2013). 
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3.3.3 TMEM27 
TMEM27 or collectrin was originally reported as a gene product (NX-17) 
upregulated in uninephrectomized mice (Zhang et al., 1999). Further analysis has 
revealed a gene localized on chromosome Xp22 which encodes a 222 amino acid 
protein (Zhang et al., 2001). Due to its close proximity with ACE2 on the genome 
and the 48% identity, TMEM27 and ACE2 have been proposed to constitute an 
ancient gene duplication (Chou et al., 2006). However, TMEM27 lacks the catalytic 
domain and it does not seem to play a crucial role in the RAS although an 
implication in the development of salt sensitive hypertension has been suggested 
(Yasuhara et al., 2008). 
Expression of TMEM27 was initially restricted to the cytoplasm and apical 
membrane of renal collecting ducts, hence the name collectrin (Zhang et al., 2001). 
Further studies have demonstrated a broader expression in pancreatic β-cells and 
renal proximal tubules (Akpinar et al., 2005; Fukui et al., 2005; Danilczyk et al., 
2006). 
TMEM27 is a type I membrane protein with an N-terminal extracellular domain. It 
has two predicted N-glycosylation sites and runs at 43 kDa under reducing 
conditions. However, TMEM27 is also observed as a dimer of 90 kDa (Akpinar et 
al., 2005). It is a selective substrate of the beta site amyloid precursor protein 
cleaving enzyme 2 (Bace2). The activity of this sheddase leads to the cleavage of 
the 43-kDa TMEM27 into two products, a 25-kDa N-terminal fragment (NTF) which 
is released in the extracellular space, and a 22-kDa C-terminal fragment (CTF) 
remaining in the membrane. Interestingly, the CTF fragment is rapidly degraded by 
γ-secretase (Akpinar et al., 2005; Esterházy et al., 2011). Furthermore, the 
proteolytic activity of Bace2 has been shown to be selective for TMEM27 monomer 
but not for its dimer (Esterházy et al., 2012). 
Analysis of Tmem27 knockout mice by two independent groups has revealed the 
key role of Tmem27 as amino acid transporter partner protein (Danilczyk et al., 
2006; Malakauskas et al., 2007). Both strains were characterized by a severe 
aminoaciduria denoted by a marked crystalluria which was due to the loss in the 
urine of nearly every amino acid, especially tyrosine and phenylalanine (Danilczyk et 
al., 2006; Malakauskas et al., 2007). Tmem27 null mice were lacking the protein but 
3. INTRODUCTION 
 
13 
 
not the mRNA expression of several amino acid transporters in the proximal tubules. 
Further analysis has revealed a non-covalent interaction of TMEM27 with several 
amino acid transporters, including Slc6a19 (B0AT1), Slc6a18 (B0AT3), Slc6a20 
(SIT1) and Slc1a1 (EAAT3). In vitro studies have shown that the function and 
surface expression of B0AT1 is increased by the presence of TMEM27, suggesting 
a chaperone function (Danilczyk et al., 2006; Malakauskas et al., 2007). TMEM27 
has been shown to bind to the N-ethylmaleimide-sensitive fusion attachment 
receptor (SNARE) complex proteins by directly interacting with snapin, a SNAP-25 
binding protein (Fukui et al., 2005) Studies on EAAC1 have reported the crucial role 
of SNARE complexes in the transporter trafficking (Fournier and Robinson, 2006), 
supporting the role of TMEM27 as chaperone protein for B0AT1. 
The promoter of TMEM27 has been shown to be under control of the hepatocyte 
nuclear factor 1α and 1β (HNF-1α and 1β) (Akpinar et al., 2005; Fukui et al., 2005; 
Zhang et al., 2007). Interestingly, HNF-1α null mice were characterized by diabetes 
and a general defect in proximal tubules reabsorption consistent with the Fanconi 
syndrome (Pontoglio et al., 1996). Further localization of HNF-1α in renal proximal 
tubules and similar phenotype in Tmem27 null mice have suggested that the 
expression of Tmem27 in proximal tubules is transcriptionally regulated by HNF-1α. 
In contrast to the proximal tubules, transcription of Tmem27 in the collecting ducts is 
controlled by HNF-1β. There, Tmem27 has been shown to play a role in primary 
cilium formation and cell polarity through vesicles transport mediation (Zhang et al., 
2007). Tmem27 expression in pancreatic β-cells is also controlled by HNF-1α. 
However, its biological role in the endocrine pancreas is still debated. In vivo studies 
reported the importance of Tmem27 in insulin exocytosis (Fukui et al., 2005; Altirriba 
et al., 2010), pancreatic β-cell proliferation (Akpinar et al., 2005) and insulin 
sensitivity (Malakauskas et al., 2009). Surprisingly, Tmem27 null mice exhibited no 
difference in pancreatic phenotype compared with wild-type animals but had altered 
glucose homeostasis (Malakauskas et al., 2009). However, the authors did not 
exclude that a compensatory mechanism by ACE2 or other proteins could mask the 
effect of Tmem27 deletion in the endocrine pancreas. 
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3.4  Amino acids 
 
3.4.1 Structure 
Amino acids are organic compounds characterized by an amino (-NH2) and a 
carboxyl (-COOH) group bound to a central carbon (C). The side chain (R group) is 
what makes each amino acid unique. With the exception of glycine, all amino acids 
exhibit optical activity due to the presence of a chiral center (α-carbon atom) and 
they can have L- or D-isoforms (Fig. 6). More than 300 amino acids exist in nature; 
only 20 of them serve as building blocks for proteins and they are called 
proteinogenic amino acids. Accordingly to the international IUPAC nomenclature 
those amino acids are classified with a trivial name (i.e. alanine), a symbol code (Ala 
or A) and a systematic name (2-aminopropanoic acid) (1976). For convenience, in 
this work we refer to the 3-letter code or to the trivial name, always implying the L-
isoform. 
 
Figure 6. Amino acid chemical structure. Amino acids consist of an amino group (-NH2), a 
carboxyl group (-COOH) and the side chain (R group) bound to a central carbon (α-carbon). H atoms 
in white, N atom in blue, C atoms in black and O atoms in red. Figure taken from 
http://wellcomeimages.org. 
 
Due to their complexity and heterogeneity, amino acids have required several 
classifications. Nine amino acids (histidine, isoleucine, leucine, lysine, methionine, 
phenylalanine, threonine, tryptophan and valine) are defined essential amino acids 
as they cannot be synthesized de novo by the body and therefore have to be 
introduced through the diet. In contrast, non-essential amino acids are defined as 
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those amino acids which can be synthesized in adequate amounts by the body 
through the process of transamination. This classification is generally flexible as 
some amino acids can become conditionally essential in infants, during growth, 
premature birth or cirrhosis (Table 1). 
Another classification of amino acids is based on the chemical structure of the 
side chain. Amino acids with an aromatic ring (phenylalanine, tyrosine and 
tryptophan) are defined as aromatic amino acids. Leucine, isoleucine and valine are 
classified as branched chain amino acids, due to their aliphatic side-chains with a 
branch.   
 
Essential Non-essential 
Histidine Alanine 
Isoleucine Argininea 
Leucine Asparagine 
Lysine Aspartate 
Methionine Cysteinea,b,c 
Phenylalanine Glutamate 
Threonine Glutamine 
Tryptophan Glycine 
Valine Prolinea,b 
Serine 
Tyrosinec 
 
Table 1. Essential and non-essential amino acids. Conditionally essential amino acids during 
growtha, premature birthb and cyrrosisc. Table modified from (Gropper, 2005). 
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3.4.2 Metabolism 
In physiological conditions, plasma amino acid concentrations are tightly 
regulated and may vary within fixed limits (Cynober, 2002). After a meal, the liver 
takes up about 50-65% of the amino acids circulating in the blood and adjusts the 
rate of their metabolism according to the needs of the body (Gropper, 2009). 
Amino acids are generally not used for energy production when carbohydrates or 
lipids are available to the organism. Instead amino acids are typically used to 
synthesize proteins and peptides, nitrogen atoms for the synthesis of other amino 
acids and nitrogenous or non nitrogenous compounds.   
Although every amino acid undergoes a unique catabolic pathway, most of the 
amino acids follow a common route. The first step in amino acid conversion is the 
removal of the amino group from the amino acid through either transamination or 
deamination. The reaction of transamination involves the transfer of the amino 
group from an amino acid to an α-keto acid (the carbon skeleton) to form the 
analogous amino acid and to produce the α-keto acid of the original amino donor. 
This reaction is catalyzed by transaminases and it is an important step in the 
synthesis of non essential amino acids. The most usual and major α-keto acid 
involved in transamination is α-ketoglutarate. In contrast to the transamination, 
deamination reaction involves only the removal of an amino group, without direct 
transfer to another compound. The product of this reaction is another amino acid or 
an α-keto acid. Deamination reaction is carried out by specialized enzymes such as 
lyases, dehydratases or dehydrogenases. The toxic ammonia generated during 
deamination of amino acids will be safely removed from the system through the urea 
cycle. Once an α-keto acid is formed, it can be further metabolized and used to 
produce glucose, ketone bodies, cholesterol or fatty acids. The potential use of 
carbon skeletons depends on the amino acid it originates from but also on the 
physiological nutritional state of the body.  
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3.5  Amino acid sensing 
Plasma amino acid concentrations can be challenged under physiological or 
pathophysiological conditions such as protein undernutrition, imbalanced diet or 
several forms of stress (trauma, thermal burn, sepsis, fever, etc.) (Chaveroux et al., 
2010). In these conditions, higher eukaryotes have developed a finely tuned 
response in order to immediately adapt their metabolism accordingly. It is now well 
established that changes in amino acid availability, in addition to an endocrine and 
neuronal response, trigger cell-signaling events and regulate gene expression as 
well as transport and metabolism of amino acids themselves (Fafournoux et al., 
2000; Kilberg et al., 2005; van Zeebroeck et al., 2008). Mammalian cells have two 
recognized pathways for controlling and responding to amino acid availability. 
Amino acid abundance in mammalian cells activates the mammalian target of 
rapamycin (mTOR) pathway that ultimately sustains anabolism and inhibits 
catabolism (Dennis et al., 1999; van Sluijters et al., 2000). In contrast, when amino 
acids are scarce, the general control nonrepressed 2 (GCN2) pathway is activated. 
As a result of this signaling cascade activation, general protein synthesis is 
decreased. Although these two pathways affect protein synthesis in opposite 
directions, it is not yet clear whether they are directly linked to each other (Kilberg et 
al., 2005). 
 
3.5.1 GCN2 pathway 
Eukaryotic cells sense amino acid deficiency through an accumulation of 
uncharged tRNAs which bind to and activate the GCN2 protein kinase (Berlanga et 
al., 1999; Sood et al., 2000; Zhang et al., 2002). GCN2 protein kinase 
phosphorylates and inactivates the eukaryotic initiation factor 2α (eIF2α), which in 
turn leads to a decrease of global mRNA translation (Kimball, 2002; Zhang et al., 
2002). However, selected mRNAs with specific regulatory elements in their 5’-UTRs 
exhibit increased translation under the same circumstances. This phenomenon, 
known as translational derepression, was first described for the yeast transcription 
factor GCN4 (Hinnebusch, 1997), and then shown for the mammalian GCN4 
homologue, activating transcription factor 4 (ATF4) (Harding et al., 2000). These 
transcription factors are able to bind to the Amino Acid Response Element (AARE) 
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sequences in the promoter region of selected genes and upregulate their 
transcription. Two sets of genes regulated by amino acid limitation have been 
identified: genes that are down- or up-regulated (Harding et al., 2003; Deval et al., 
2009). Genes involved in regulation of transcription, signal transduction, lipid and 
carbohydrate metabolic processes, etc. are mostly downregulated (Deval et al., 
2009). Among the genes which are upregulated by amino acid limitation, several 
ones encoding for amino acid transporters (SLC7A1, SLC38A2 and SLC7A5), 
transcription factors (ATF3, c-jun, C/EBPα), and ribosomal proteins have been 
identified. The molecular mechanisms involved in the regulation of gene expression 
by amino acid limitation cover multiple steps along the pathway of DNA to RNA to 
protein (Kilberg et al., 2005). Beside the already mentioned transcriptional regulation 
through AARE sequences in the promoter region, two more main mechanisms of 
gene expression regulation by amino acid deficiency have been described. The first 
one involves stabilization of mRNA following amino acid limitation. Specific mRNAs 
present AU- rich elements (ARE) sequences in the 3’-untranslated region (3’-UTR) 
where regulatory proteins bind and control mRNA degradation or stabilization. 
Similar regulation has been described for the amino acid transporter CAT-1 (Yaman 
et al., 2002) and the activating transcription factor 3 (ATF3) (Pan et al., 2005). The 
third mechanism of gene expression regulation by amino acid deprivation involves 
the translational control of mRNA. The 5’-untranslated region (5’-UTR) of specific 
mRNAs contains upstream open reading frames (uORFs) which induce translation 
when cap-dependent protein synthesis is decreased. Examples of this mechanism 
have been observed for the activating transcription factor 4 (ATF4) (Vattem and 
Wek, 2004) and CAT-1 (Fernandez et al., 2002). 
GCN2 activation is known to occur upon depletion of any essential, non essential 
or conditionally essential amino acids, whether this is due to dietary, enzymatic or 
pharmacological reasons (Gallinetti et al., 2013). GCN2 is only one of four kinases 
which target eIF2α and that collectively are activated by various cellular stresses 
(Fig. 7).   
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 Figure 7. Amino acid response pathway. Several cellular stress signals activate the four eIF2α 
kinases GCN2, double-stranded RNA-activated protein kinase (PKR), double-stranded RNA 
activated protein kinase-like ER kinase (PERK), and heme-regulated inhibitor kinase (HRI), which in 
turn phosphorylate eIF2α and lead to a translational repression but a paradoxical increase in 
translation of ATF4. ATF4 upregulates the transcription of target genes encoding amino acid 
transporters (SLC7A1 and SLC38A2), transcription factors (CHOP) or amino acid metabolic enzymes 
(ASNS). Figure modified from (Kilberg et al., 2005). 
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3.5.2 Amino acid signaling in mTOR pathway 
The mammalian Target of Rapamycin (mTOR) is a highly conserved Ser/Thr 
kinase which plays a pivotal role in regulating cellular homeostasis and metabolism. 
Originally discovered in Saccharomyces cerevisiae as a direct result of the 
identification of its specific inhibitor rapamycin (Heitman et al., 1991), it is highly 
conserved from yeast to mammals. The mTOR kinase forms a part of two distinct 
complexes, mTORC1 and mTORC2. Although both complexes are stimulated by 
growth factors, only mTORC1 is sensitive to rapamycin and nutrients, including 
amino acids. Furthermore, they have separate downstream targets and functions. 
Besides mTOR, mTOR complex 1 (mTORC1) comprises the regulatory-
associated protein of mTOR (Raptor), the proline-rich Akt substrate 40 kDa 
(PRAS40), DEP domain-containing mTOR-interacting protein (Deptor), and the 
mammalian lethal with SEC13 protein 8 (mLST8). In contrast to the positively 
regulator mLST8 (Kim et al., 2003), both Deptor (Peterson et al., 2009) and 
PRAS40 (Sancak et al., 2007; Vander Haar et al., 2007) inhibit mTORC1 activity. 
Raptor is indispensable for substrate recognition but it is not yet clear whether it is a 
positive or negative regulator of mTORC1 activity (Yang and Guan, 2007). 
In presence of favorable signals such as nutrients, growth factors and energy, 
mTOR promotes cellular growth by stimulating biosynthetic pathways, including 
protein synthesis. In contrast, during nutrient starvation, hypoxia or osmotic stress 
mTOR is inhibited and autophagy is promoted. Among the nutrients, amino acids 
play a pivotal role in mTOR activation, although it is currently unclear how amino 
acid sufficiency or limitation is sensed to modulate mTORC1 activity. Leucine, 
arginine and glutamine are the three most potent amino acids involved in mTOR 
activation (Hara et al., 1998; Nakajo et al., 2005). Amino acids are known to act 
directly through the Rheb small GTPase and independently on TSC1/2, a direct 
upstream regulator of Rheb (Roccio et al., 2006). Like other small GTPases, Rheb 
activation state depends on the GTP/GDP binding. The presence of amino acids 
favors a Rheb GTP-bound active state which is a potent activator of mTORC1 
kinase activity. Alternatively, amino acid deprivation promotes Rheb-GTP hydrolysis, 
resulting in the inactive GDP-bound state. Recently, new molecular players in the 
upstream amino acid signaling have been identified at the lysosome surface and a 
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model has been proposed. Sabatini and coworkers have suggested that amino 
acids signal their availability from within the lysosome through the vacuolar H+-
ATPase (v-ATPase) (Fig. 8). Amino acid stimulation weakens the interaction 
between one of the v-ATPase subunit (V1) and Ragulator, a novel protein complex 
which functions as guanosine exchange factor (GEF). Hence, Ragulator is able to 
activate another GTPase, named RAG GTPase. Once activated, the RAG complex 
recruits mTORC1 from the cytosol to the lysosome, where it becomes activated 
(Sancak et al., 2007; Sancak et al., 2008). 
Figure 8. mTOR activation mechanism. Amino acids are sensed by the lysosomal v-ATPase, 
which controls the RAG GTPase-Ragulator binding and therefore Ragulator guanine exchange factor 
(GEF) activity. The active RAG complex, constituted of RAG A/B•GTP – RAG C/D•GDP binds to 
mTORC1 and recruits it to the lysosome, where RHEB can activate it. Figure taken from (Jewell et 
al., 2013). 
 
The best studied mTORC1 downstream effectors are the translational regulators 
S6K1 (p70 ribosomal protein S6 kinase 1) and 4E-BP1 (eIF4E binding protein 1) 
(Fingar and Blenis, 2004). In their unphosphorylated state, both S6K1 and 4E-BP1 
are bound to eIF3 (eukaryotic initiation factor 3) and remain inactive (Holz et al., 
2005). Upon growth stimuli, mTORC1 binds to eIF3, phosphorylates S6K1 and 4E-
BP1 and release them from the eIF3 complex. Once activated, 4E-BP1 and S6K1 
enhance protein synthesis by increasing the initiation and progression of mRNA 
translation, respectively. Under basal conditions, 4E-BP1 binds and inhibits eIF-4E 
(eukaryotic translation initiation factor 4E). Upon phosphorylation by mTORC1, 4E-
BP1 dissociates from eIF-4E, which in turn can bind the mRNA cap and initiate the 
translation (Haghighat et al., 1995; Hara et al., 1997). The active S6K1 also 
promotes mRNA translation by phosphorylating multiple key proteins involved in 
translation initiation and/or elongation (Jeno et al., 1988; Thomas, 2002). 
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3.5.3 Amino acid transceptors 
Since amino acid transporters represent the natural bridge between cell and 
environment, there is growing recognition that they might have a role in nutrient 
sensing and signaling (Hundal and Taylor, 2009). Examples of amino acid 
transporters playing the double transporter/receptor role (so called “transceptors”) 
have been already described in lower eukaryotes such as Saccharomyces 
cerevisiae and Drosophila melanogaster. The yeast amino acid permeases Ssy1 
(Didion et al., 1998; Klasson et al., 1999) and Gap1 (Donaton et al., 2003) are 
considered to function as sensor of extracellular amino acid availability since they 
both stimulate signaling pathways which evoke changes in metabolism and 
expression of a variety of stress-responsive genes. Two amino acid transporter 
genes have been identified in Drosophila as important regulator of growth and 
proliferation: slimfast (Colombani et al., 2003) and path (Goberdhan et al., 2005). 
The major example of transporter-like sensor in mammalian cells is represented by 
SNAT2 (SLC38A2), a member of the APC transporter superfamily to which Gap1, 
Ssy1, slimfast and PATH belong (Jack et al., 2000). Two independent lines of 
evidence indicate a potential role for SNAT2 in amino acid signaling. The increase in 
SNAT2 gene expression and surface localization in response to amino acid 
deprivation suggest an adaptive regulation of the amino acid transporter which may 
help to adjust the intracellular amino acid pool accordingly to extracellular amino 
acid availability (Gazzola et al., 2001; Hyde et al., 2001). Secondly, SNAT2 has 
been shown to affect insulin signaling through phosphoinositide 3-kinase (PI3K), 
therefore affecting the downstream mTOR pathway (Evans et al., 2008). This study 
suggests that SNAT2 may be able to signal directly to mTOR and modulate the 
intracellular amino acid concentrations. 
Two mechanisms by which amino acid transporters may generate an amino 
acid-dependent cell signaling have been proposed (Hyde et al., 2003). In the first 
mechanism the amino acid transporter itself functions as a sensor and directly 
responds to changes in substrate availability generating cellular signaling. 
Alternatively, the amino acid transporter may affect the local amino acid 
concentrations and therefore modulate the initiation of signaling by intra- or extra-
cellular receptors situated in its proximity. 
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3.6 Arginine 
Among the 20 proteinogenic amino acids, arginine represents an interesting 
molecule. In healthy adults, arginine can be synthesized de novo from glutamine 
and citrulline. However, in certain conditions, as for example renal or intestinal 
dysfunction and inflammation, or in newborns and growing children, arginine must 
be introduced in the diet. Thus, arginine is classified as a conditionally essential 
amino acid (Flynn et al., 2002). 
 
3.6.1 Arginine metabolism 
The appearance of arginine in plasma in the fed status is both exogenous (diet) 
and endogenous (protein catabolism and endogenous synthesis). Plasma levels of 
arginine in healthy adults are ~ 80-120 µmol/L and are maintained fairly constant by 
the organism (Morris, 2007). The anabolic and catabolic pathways in which arginine 
is involved will be discussed in more details in the next sections. 
 
3.6.1.1 Arginine anabolism 
De novo arginine synthesis in adult animals and humans is negligible compared 
to the endogenous arginine flux deriving from protein catabolism (Wu and Morris, 
1998). Arginine synthesis is the result of an interorgan communication between 
intestine and kidney known as intestinal-renal axis (Wu and Morris, 1998). In healthy 
adults, glutamine, glutamate and proline are converted into citrulline in the 
enterocytes (Wu and Morris, 1998). Plasma citrulline bypasses the liver without 
being taken up and reaches the renal proximal tubules where it is reabsorbed and 
converted into arginine by argininosuccinate synthetase (ASS) and 
argininosuccinate lyase (ASL) (Wu et al., 2007). The kidney is the major organ 
involved in arginine production as the renal arginine synthesis accounts for 
approximately 60% of the net arginine synthesis. In newborn and young infants, 
however, arginine synthesis occurs already at the level of the intestine. Due to an 
increased capacity of the kidney to synthesize arginine from glutamine, the intestinal 
synthesis of arginine is gradually decreased during development (Hurwitz and 
Kretchmer, 1986; Morris et al., 1991; Wu and Knabe, 1995). 
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The highest rate of arginine synthesis occurs in the liver where arginine is 
synthesized via the urea cycle. However, the net arginine synthesis by the liver is 
negligible because hepatocytes express high arginase levels which hydrolyze 
arginine into urea and ornithine (Wu and Morris, 1998). 
 
3.6.1.2 Arginine catabolism 
In contrast with the single anabolic pathway, arginine breakdown appears to be 
very complex, due to the large systemic and subcellular compartmentalization (Wu 
and Morris, 1998). Four enzymes are using arginine as substrate: arginase, nitric 
oxide synthase (NOS), arginine decarboxylase and arginine:glycine 
amidinotrasferase. The action of these enzymes results in production of several low 
molecular weight molecules which can be further metabolized (Fig. 9). 
Figure 9. Pathways of arginine catabolism. Enzymatic pathways are schematic and not all 
substrate intermediates are shown. Enzymes which catalyze the reactions are: 1. arginine 
decarboxylase; 2. NOS; 3. arginase; 4. arginine:glycine amidinotransferase; 5. guanidinoacetate N-
methyltransferase; 6. ornithine decarboxylase; 7. spermidine synthase; 8. spermine synthase. 
Abbreviations: SAM, S-adenosylmethionine; SAHC, S-adenosylhomocysteine; DCAM, 
decarboxylated S-adenosylmethionine; MTA, methylthioadenosine.  Figure modified from (Wu and 
Morris, 1998). 
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Arginase. In mammals, the hydrolysis of arginine to ornithine and urea by 
arginase is quantitatively the most important pathway for arginine catabolism (Wu et 
al., 2009). Two isoforms of arginase exist and they are encoded by separate genes. 
Type I arginase is mostly expressed in the liver where it plays a major role in the 
urea cycle. Type II arginase is completely absent from the liver but has low 
expression levels in kidney, brain, small intestine, mammary gland and 
macrophages (Morris et al., 1997). In contrast to the cytosolic localization of type I, 
type II arginase is a mitochondrial enzyme and its subcellular compartmentalization 
might be a mechanism for regulating the metabolic fate of arginine, as already 
shown in enterocytes (Davis and Wu, 1998). 
NOS. The family of nitric oxide synthases has been for the past several years 
the best known group of arginine-metabolizing enzymes, mostly thanks to the 
diverse roles played by nitric oxide (NO) as signaling molecule (Wu and Morris, 
1998). NOSs convert arginine into NO and citrulline in a relatively low percentage 
compared with overall arginine catabolism (Wu and Morris, 1998). There are three 
distinct isoenzymes of NOS, encoded by separate genes: type I or neuronal NOS 
(nNOS), type II or inducible NOS (iNOS) and type III or endothelial NOS (eNOS). 
The constitutive nNOS and eNOS are primarily expressed in neurons and 
endothelial cells, respectively. Expression of iNOS can be induced by bacterial 
endotoxin and inflammatory cytokines in a wide range of cells and tissues (Pautz et 
al., 2010). In contrast to the Ca2+-independent iNOS, activity of the constitutive NOS 
isoenzymes is highly regulated by Ca2+/calmodulin. 
Arginine decarboxylase. The conversion of arginine to agmatine is mediated by 
arginine decarboxylase. Originally described in plants and bacteria, arginine 
decarboxylase is expressed in the mitochondria of several mammalian cell tissues, 
including brain, liver, kidney, adrenal gland, macrophages and gut (Li et al., 1994; 
Morrissey et al., 1995; Sastre et al., 1998). Agmatine has been shown to play a role 
as cell signaling molecule (Li et al., 1994), anti-proliferative agent (Satriano et al., 
1998) and endogenous regulator of NO synthesis (Galea et al., 1996). 
Arginine:glycine amidinotrasferase. The first reaction in creatine synthesis is 
mediated by arginine:glycine amidinotransferase, which transfers the guanidine 
group from arginine to glycine to originate guanidinoacetate and ornithine. The 
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expression of this enzyme is mostly predominant in kidney and pancreas, although it 
has been shown to be localized in the liver and other organs as well (McGuire et al., 
1986). Guanidinoacetate is methylated by guanidinoacetate N-methyltransferase to 
form creatine, which is transported in the blood to be used by skeletal muscles and 
nerves as energy source. 
Ornithine decarboxylase. Polyamines are small molecules playing an essential 
role in cell proliferation and differentiation (Pegg, 1986). The most important 
polyamines are putrescine, spermidine and spermine. The synthesis of putrescine 
occurs through decarboxylation of ornithine by ornithine decarboxylase (ODC). ODC 
is considered the rate-limiting enzyme in the polyamine metabolism and it is 
regulated by hormones and growth factors (Janne and Raina, 1969; Bello-
Fernandez et al., 1993). Spermidine is synthesized by spermidine synthase through 
the addition of the amino propyl group of the decarboxylated S-adenosylmethionine 
(DCAM) to putrescine. Subsequently, spermine is synthesized after fusing 
spermidine with another amino propyl group, DCAM, to spermidine. 
 
3.6.2 Renal arginine transport 
Reabsorption of arginine in the kidney involves specific amino acid transporters 
on the apical and basolateral membranes of proximal tubular cells. The apical 
uptake of arginine from the tubular fluid is mediated by the heterodimeric amino acid 
transporter b0,+AT-rBAT. The light subunit b0,+AT (SLC7A9) is covalently linked by a 
disulfide bond to the heavy subunit rBAT (SLC3A1) (Pfeiffer et al., 1999a; Wagner 
et al., 2001). b0,+-rBAT functions as a high affinity antiporter, which exchanges large 
neutral amino acids (especially cystine) against dibasic (arginine, lysine, ornithine) 
amino acids (Chillarón et al., 1996). Defects in the transporter are known to cause 
cystinuria, an autosomal disease characterized by elevated urinary cystine, arginine, 
lysine and ornithine. Inheritance can be dominant or recessive and mutations can 
affect both b0,+AT and rBAT genes (Calonge et al., 1994; Chillarón et al., 2010). 
 Arginine transport across the basolateral membrane is mediated by the system 
y+, mainly by CAT1 (SLC7A1) and y+LAT1-4F2hc (SLC7A6-SLC3A2). CAT1 was 
originally described as the receptor for murine ecotropic leukaemia retrovirus (Kim 
et al., 1991). It mediates Na+-independent transport of cationic amino acids and it is 
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considered to be the major system y+ transporter in most cells (Verrey et al., 2004). 
CAT-1 expression is regulated by amino acid limitation (Hyatt et al., 1997). Removal 
of a single essential amino acid or all amino acids induces an increase of CAT-1 
protein expression through transcriptional and posttranscriptional mechanisms 
(Hatzoglou et al., 2004). CAT-1 gene shows an AARE sequence within the first exon 
of the genomic sequence which mediates the transcriptional activation upon amino 
acid deprivation (Fernandez et al., 2003). Furthermore, regulatory proteins are 
known to associate with CAT-1 mRNA and stabilize it (Yaman et al., 2002). In 
addition to the transcription upregulation and the increase of mRNA stability, CAT-1 
translation is also regulated following amino acid deprivation. The internal ribosome 
entry sequence (IRES) in CAT-1 mRNA allows an m7G-cap independent translation 
initiation, resulting in an increase of CAT-1 protein synthesis (Fernandez et al., 
2001; Fernandez et al., 2002). 
y+LAT1 and 4F2hc form a heterodimeric amino acid transporter which mediates 
the efflux of cationic amino acids in exchange for neutral amino acids and Na+ 
(Pfeiffer et al., 1999b; Fukasawa et al., 2000). Mutations in y+LAT1 cause lysinuric 
protein intolerance, an autosomal recessive disease characterized by low plasma 
and elevated urine concentrations of cationic amino acids. Because y+LAT1 is 
expressed in both the intestine and the kidney, defects in its function result in an 
impaired intestinal absorption and renal reabsorption. Patients manifest also 
hyperammonemia, caused by an impaired urea cycle, and develop an aversion to 
protein-rich foods (hence the name) (Borsani et al., 1999; Torrents et al., 1999). 
The tertiary active function of b0,+AT-rBAT and y+LAT1-4F2hc relies on the 
parallel function of the apical B0AT1/SLC6A19 and basolateral TAT1/SLC16A10, 
respectively. In fact, the obligatory antiporters b0,+AT-rBAT and y+LAT1-4F2hc 
recycle the neutral amino acids transported by B0AT1 and TAT1 in exchange for 
cationic amino acids. 
Since the kidneys are the main site of arginine de novo synthesis from citrulline, 
the transport of this amino acid is crucial for arginine homeostasis. The renal tubular 
citrulline uptake is most likely mediated by the apical B0AT1 and b0,+AT-rBAT 
(Mitsuoka et al., 2009) and by the basolateral OAT1 (SLC22A6) (Nakakariya et al., 
2009). 
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Figure 10 summarizes the major arginine, citrulline and ornithine transporters 
and the metabolic pathways in which arginine is involved in renal epithelial cells. 
Figure 10. Schematic overview of the crosstalk between arginine, citrulline and ornithine 
transporter and their metabolism in renal epithelial cells. Apical b0+-rBAT transporter uptakes L-
arginine (R) in exchange for neutral amino acids (AA0), driven by the transport of B0AT1, which takes 
up neutral amino acids as well as citrulline. On the basolateral membrane OAT1 likely mediates 
citrulline uptake. R efflux is mediated by y+LAT1-4F2hc in exchange for aromatic AA0, which are 
likely recycled by the facilitated diffusion pathway TAT1. Additionally, R may be exported by 
basolateral CAT1.  In the cytoplasm, citrulline is converted to R via the sequential action of 
arginosuccinate synthetase (ASS) and arginosuccinate lyase (ASL). R is converted back to citrulline 
by NOS, which in addition generates nitric oxide (NO). In the mitochondria, R is metabolized by 
different pathways. Metabolism of R by arginine:glycine amidotransferase (AGAT) produces ornithine 
and guanidinoacetate (GAA). This reaction can also occur in the cytoplasm and the GAA is released 
in the blood stream for creatine production. R can be decarboxylated by arginine decarboxylase 
(ADC) to agmatine and CO2. Mitochondrial argininase II hydrolyzes R to produce ornithine. Ornithine 
can be converted to citrulline by ornithine transcarbamoylase (OTC). Enzymatic pathways are 
schematic and not all substrate intermediates are shown. Dotted lines indicate either translocation of 
substrates, eg., through the cytoplasm or extracellular space, or multiple metabolic steps. Figure 
taken from (Makrides et al., 2014) 
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3.7 Thesis projects 
 
1. Role of TMEM27 for the function and surface expression of B0AT1 in renal 
epithelial cells 
 Here we characterize the cellular and molecular mechanisms underlying the 
interaction between the amino acid transporter B0AT1 and the accessory protein 
TMEM27 in the kidney. An MDCK cell line overexpressing B0AT1 and TMEM27 was 
chosen as in vitro model for our study. 
 
2. Role of amino acids for the regulation of B0AT1 expression in renal 
epithelial cells 
 Here we investigate the impact of amino acid concentrations on the expression 
of the amino acid transporter B0AT1 and the accessory protein TMEM27 in MDCK 
cells. The results of this study are summarized in the manuscript entitled “Amino 
acids regulate transgene expression in MDCK cells”. 
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4. B0AT1-TMEM27 INTERACTION PROJECT 
 
 
4.1 Materials and methods 
 
4.1.1 Cell lines 
The Madin Darby Canine Kidney (MDCK, strain I) cell line was used as in vitro 
model for our studies. MDCK cells derived from the distal tubules of canine kidney 
and they grow as tight polarized monolayers when cultured on porous filter 
substrates (Simmons, 1981). Cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM; catalog no. E15-810, GE Healthcare) supplemented with 10% 
heat-inactivated FBS (Sigma-Aldrich #F7524), 2 mM L-glutamine and 1% non 
essential amino acids (NEAA; catalog no. M11-003, GE Healthcare) at standard cell 
culture conditions (37°C, 95% relative humidity and 5% CO2). The growth medium 
was changed every second day and the cells were splitted (1:10 to 1:20) two times 
per week. To allow cell polarization, cells were seeded at confluent density 
(1.7·105 cells/cm2) and cultivated on Corning Costar Transwell filters for 6 days in 
standard cell culture medium. 
Human embryonic kidney cells (HEK293), kindly provided by Dr. D. Schümperli 
(University of Bern) were grown in DMEM (catalog no. E15-810, GE Healthcare) 
supplemented with 10% heat-inactivated FBS (Sigma-Aldrich), 2 mM L-Glutamine 
and 1% non essential amino acids at standard cell culture conditions (37°C, 95% 
relative humidity and 5% CO2). Upon reaching 80-90% confluency, cells were 
trypsinized and passaged at a density of 10%. 
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4.1.2 cDNA constructs, transfection and lentiviral transduction 
All vectors required to produce lentiviruses were designed by the Tronolab 
(EPFL, Lausanne). The envelope plasmid pMD2.G and the packaging plasmid 
pCMV-dR8.91 were obtained via Addgene (www.addgene.org), whereas the 
lentiviral vectors pLVCT-tTRKRAB-dsRed and pLV-T-EGFP were kindly provided by 
prof. D. Schümperli (University of Bern). The human B0AT1 and TMEM27 coding 
sequences were subcloned in pLV-T-EGFP in place of EGFP sequence. Bulk 
production of the different plasmids and vectors was performed transforming HB101 
E.coli cells with the constructs, followed by midi-prep DNA extraction kit (Qiagen). 
HEK293T (below passage 20) were cultured according to the cell culture 
protocol. For transfection procedure, HEK293T were counted and 4-5·106 cells were 
seeded on 10 cm dishes and allowed to attach overnight. The following day, 
medium change was performed two hours before transfection. The transfection 
mixture was prepared as follows: 5 μg of pMD2.G, 10 μg of pCMV-pR8.91 and 
15 μg of the vector of interest. Volume was adjusted to 450 μL with 0.1x TE buffer 
pH 8.8. 50 μL of 2.5 M CaCl2 were added dropwise to the DNA mixture and the 
volume was adjusted to 500 μL with 2x HBS, mixed well and let complex for at least 
20 min at RT. DNA transfection mixture was added dropwise to the cell culture dish 
and medium was exchanged the next morning. The supernatant was collected from 
transfected HEK293T cells 48 hours post transfection, filtered through 0.45 µm 
filters and centrifuged at 25000 rpm (Sorvall® Ultraspeed Centrifuge/Rotor TH64I) 
for 90 min at 4°C. Supernatant was aspirated almost completely and the invisible 
pellet was resuspended in approx. 1 mL of the same medium. The same day of 
virus harvesting, MDCK cells were trypsinized, counted and 1·106 cells were 
resuspended with the virus containing medium and plated on a 35 mm petri dish. 
After overnight incubation, the medium was replaced with MDCK standard medium 
and the cells were allowed to reach confluency.  
MDCK cells inducibly overexpressing B0AT1 and/or TMEM27 were obtained as 
shown in Figure 11. After the third transduction, cells were cloned by limiting 
dilution. Aliquots of cell suspension corresponding to 0.5, 1 or 2 cells were seeded 
in 96-well plates and monitored for two weeks. Cell populations deriving from one 
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single cell were selected and tested for the inducible and stable expression of 
B0AT1 and/or TMEM27 by RT-PCR and Western blotting. 
Figure 11. Sequential cotransduction of MDCK cells with KRAB, B
0
AT1 and TMEM27 
constructs. MDCK-KRAB cells were first transduced either with B
0
AT1 or with TMEM27 constructs. 
Obtained cell lines were secondly transduced with B
0
AT1 or with TMEM27 construct resulting in 
either double transduced B0AT1 or double transduced TMEM27 or B
0
AT1-TMEM27 co-expressing 
cell lines. 
 
4.1.3 Western Blotting 
MDCK cells grown on plastic supports (6-well plates or 10 cm dishes) or 
polycarbonate filters (24 mm filters) were washed once with ice-cold PBS, scraped 
from their support in 500-1000 μL of ice-cold PBS and centrifuged at 2000 g for 
2 min at 4°C. Cell pellet was then homogenized by vigorous pipetting in 20-200 μL 
of ice-cold Radio-Immunoprecipitation Assay (RIPA) buffer (150 mM NaCl, 50 mM 
Tris pH 7.4, 1% NP-40, 0.5% Na-Deoxycholate) supplemented with fresh Protease 
Inhibitor Cocktail (Sigma-Aldrich) and incubated for 40 min on ice. Cell debris was 
pelleted with centrifugation at 2500 g for 10 min at 4°C and the supernatant was 
either used immediately for protein quantification or snap frozen and stored at 
-80°C. Protein sample concentration was determined by DC-Protein Assay, 
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following the manufacturer’s guidelines (Bio-Rad) and using the BioTek Microplate 
Spectrophotometer μQuant. 
For protein deglycosylation assay, 20 μg of protein lysate were treated with N-
Glycosidase F (PNGase F) according to the manufacturer’s guidelines (New 
England Biolabs). The samples were denatured at 65°C for 15 min in the provided 
buffer containing β-Mercaptoethanol and SDS, incubated for 1 h at 37°C in reaction 
buffer with 1% NP-40 with or without added PNGase F. 
For Western blotting experiments, 20 μg of protein lysate were diluted in 
4x Laemmli buffer supplemented with 10% β-Mercaptoethanol, incubated at 37°C 
for 30 min and loaded on 10% polyacrilamide gel. After separation by 
electrophoresis, proteins were transferred to PVDF membrane (Immobilion-P, 
Millipore). Blots were blocked (1 h at RT) with 5% milk powder in Tris-buffered 
saline supplemented with 0.1% Tween-20 (TBS-T), and incubated (overnight at 4°C) 
with the primary antibody diluted in 5% milk in TBS-T as described in Table 2. After 
washing the blot with TBS-T, secondary antibody diluted in 5% milk in TBS-T was 
applied (1 h at RT) and the antibody binding was detected with Immobilion Western 
Chemiluminescent HRP substrate (Millipore) or CDP-Star (Roche) and visualized 
with FujiFilm Las-4000 camera according to the manufacturer’s instructions. Image-
J software was used for densitometric analysis of the Western blots. 
 
Table 2. List of primary and secondary antibodies used in Western blot experiments. 
Antibody Host Dilution Source Catalogue # 
B0AT1 Rabbit 1:1000 In house 
TMEM27 Mouse 1:1000 Abnova H00057393-B01P
β-Actin Mouse 1:5000 Sigma-Aldrich A5316 
Anti-rabbit, HRP conjugate Goat 1:5000 Promega W401B 
Anti-mouse, HRP conjugate Goat 1:5000 Promega W402B 
Anti-rabbit, AP conjugate Goat 1:5000 Promega S373B 
Anti-mouse, AP conjugate Goat 1:5000 Promega S372B 
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4.1.4 RNA extraction and RT-PCR 
MDCK cells were grown on plastic dishes and B0AT1 and/or TMEM27 
expression was induced for 3 days with 1 μg/mL doxycycline. Cells were washed 
once with ice-cold PBS, scraped from their support in 500-1000 μL of ice-cold PBS 
and centrifuged at 2000 g for 2 min at 4°C. RNA was isolated using RNeasy Mini Kit 
(Qiagen), following the manufacturer’s instructions. Cells-to-cDNA II kit (Applied 
Biosystems) was used to isolate RNA from MDCK clonal cell lines in the initial 
screening test. RNA concentration was measured by NanoDrop ND 1000 
(NanoDrop Technologies). 
Reverse transcription of the isolated RNA was performed with TaqMan® RT Kit 
using random hexamers (Applied Biosystems). 
Validation of exogenous B0AT1 and TMEM27 insertion into MDCK genome of 
clonal cells was performed by PCR, using primers designed for the human genes 
and listed in Table 3. Similarly, endogenous expression of TMEM27 and ACE2 was 
tested by PCR, using primers designed for the canine genes and listed in Table 3. In 
both experiments, the reaction mix consisted of 1x reaction buffer, 5 mM MgCl2, 
400 μM dNTPs, 0.1 μM of each primer, 1 U of Taq Polymerase (EurobioTaq) and 
water adjusted to a final volume of 20 μL. 5 ng of cDNA were used per reaction. 
Table 3. List of primers used for PCR analysis. 
 
 
Target mRNA Specie Primer sequence (5’→3’) 
HPRT Mouse 
Sense: TTATCAGACTGAAGAGCTACTGTAATGATC 
Antisense: TTACCAGTGTCAATTATATCTTCAACAATC
B0AT1 Human 
Sense: GTGTGGACAGGTTCAATAAGGACAT 
Antisense: CCACGTGACTTGCCAGAAGAT 
TMEM27 Human 
Sense: CCTCTTCAAAGCGATGGTAGCT 
Antisense: CCCTCTGGGTTACATTGCAAA 
TMEM27 Dog 
Sense: TCAGCCAGATGCAGAGAATG 
Antisense: CTCATGGAGAAAGCCACCAT 
ACE2 Dog 
Sense: AGCCCAACTGGATGCCTCCCA 
Antisense: TGCATCCCAGCTCTGGTTCACCA 
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The following PCR program was used: 
 
Temperature Time Cycles
94°C 2 min  
94°C 
60°C 
72°C 
30 sec 
30 sec 
30 sec 
35 
72°C 5 min  
 
Finally, PCR amplification products were separated on a 2% agarose gel 
electrophoresis and analyzed with the RedTM imaging system (Alpha Innotech). 
 
4.1.5 Immunofluorescence staining 
MDCK cells were grown on poly-D-lysine (Sigma-Aldrich) coated coverslips or 
differentiated on polycarbonate filters according to the cell culture protocol. B0AT1 
and/or TMEM27 expression was induced for 3 days (coverslips) or 2 days prior the 
seeding and the whole length of differentiation (filters) with 1 μg/mL doxycycline. 
Cells were washed once with ice-cold PBS and fixed with methanol-acetone (1:1) 
for 5 min at -20°C. Cells were washed repetitively with ice-cold PBS and incubated 
with PBS-Triton X-100/BSA (0.1%/2%) for 30 min at RT. The same blocking solution 
was used to incubate primary and secondary antibodies. Incubation with primary 
antibody was performed in a humidified chamber overnight at 4°C. After washing, 
cells were incubated for 1 h at RT with secondary antibodies. 4’,6-Diamidino-2-
Phenylindole Dihydrochloride (DAPI, Life Technologies) was added to the 
secondary antibody mixture (1:5000 dilution) in order to counterstain the nuclei. 
Coverslips or filter pieces were mounted in DAKO-Glycergel and analyzed at the 
fluorescent light microscope (Nikon) or confocal laser scan microscope (Leica). 
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Antibody Host Dilution Source Catalogue # 
B0AT1 Rabbit 1:1000 In house   
TMEM27 Mouse 1:1000 Abnova H00057393-B01P
Anti-rabbit, Alexa Fluor 594 Donkey 1:2000 Life Technologies A21207 
Anti-mouse, Alexa Fluor 488 Donkey 1:2000 Life Technologies A21202 
 Table 4. List of primary and secondary antibodies used in immunofluorescence staining 
experiments. 
 
4.1.6 Amino acid uptake 
MDCK cells were grown on filters according to the standard cell culture protocol. 
B0AT1 and/or TMEM27 expression was induced 2 days prior the seeding and then 
for the all length of differentiation with 1 μg/mL doxycycline. The trans-epithelial 
electrical resistance across intact monolayers of MDCK cells was measured using 
EVOHM device (World Precision Instruments). Cells were washed three times and 
then incubated for 30 min at 37°C with uptake buffer (150 mM NaCl, 10 mM HEPES 
pH 7.4, 1 mM CaCl2, 5 mM KCl, 1 mM MgCl2, 10 mM glucose). Fresh uptake buffer 
was then applied on the basolateral side whereas the apical compartment received 
the uptake buffer supplemented with 1 mM L-Leucine and the corresponding 3H-
labeled L-Leucine (Harmann Analytic) as tracer. 14C-labeled mannitol (Hartmann 
Analytic) was used as a control for the integrity of the cell monolayer. After 10 min 
incubation at 37°C, the uptake was stopped by replacing the apical and basolateral 
solutions with ice-cold uptake buffer. The cells were washed three times and the 
filters were excised and placed into scintillation fluid and shaked overnight at RT. 
Radioactivity was measured by liquid scintillation analyzer (Packard Tri-Carb 
2900TR, PerkinElmer). 
 
4.1.7 Immunoprecipitation 
MDCK cells were grown on 10 cm dishes and B0AT1 and/or TMEM27 
expression was induced for 3 days with 1 μg/mL doxycycline. Cell lysates were 
prepared according to the section 4.1.3. 500 mg of protein lysate were preincubated 
with primary antibodies for 3 hours at 4°C under gentle rocking. Lysates were then 
added to the 50 μL of protein A/G conjugated agarose beads slurry (Thermo 
Scientific) and incubated overnight at 4°C under gentle rocking. Beads were washed 
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three times in 50 mM NaCl, 50 mM HEPES pH 7.4, 5 mM EDTA, 1% NP-40 and 
elution of the bound proteins was performed by incubation with Laemmli buffer (with 
β-Mercaptoethanol) at 60°C for 40 min. Protein samples were then subjected to 
Western blot analysis. 
 
4.1.8 Pulse-chase analysis 
MDCK cells were grown on 60 mm dishes and B0AT1 and/or TMEM27 
expression was induced for 3 days with 1 μg/mL doxycycline. Cells were washed 
three times with methionine-free DMEM (Sigma-Aldrich) supplemented with cysteine 
and 10% FBS and then incubated in the same medium for 30 min 37°C, 5% CO2. 
The medium was exchanged for the above-mentioned medium containing 
125 µCi/mL of 35S-Methionine for 1 h at 37°C, 5% CO2. For chase experiments, 
cells were subsequently incubated in complete culture medium for the times 
indicated. Cells were then washed three times in ice-cold PBS containing Ca2+ and 
Mg2+ and cell lysates were prepared accordingly to the section 4.1.3. Incorporated 
radioactivity was determined by TCA precipitation and liquid scintillation. 
 
4.1.9 Statistics 
Analysis of the experimental data was performed by Graph Pad Prism and MS 
Office-Excel. Differences between mean values of groups were tested with one-way 
analysis-of-variance (ANOVA) followed by Tukey’s post-test. Level of significance 
are given as * = p≤0.05, ** = p≤0.01, *** = p≤0.001. Data are expressed as mean ± 
SEM. 
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4.2 Results 
 
4.2.1 Test of anti-B0AT1 and anti-TMEM27 antibodies 
 In order to study the function, localization and regulation of B0AT1 protein, 
polyclonal antibodies were raised against a C-terminal peptide of human B0AT1 by 
Pineda, Berlin. The rabbit antiserum was then affinity purified and antibody 
specificity was tested in Western blot experiments with lysates from HEK293T cells 
transiently transfected with B0AT1 (Fig. 12, Panel A). Two specific bands 
presumably corresponding to fully- and core-glycosylated B0AT1 were detected at 
100 kDa and 72 kDa, respectively. Treatment with PNGase F showed a double 
band around 55 kDa corresponding to the deglycosylated B0AT1. In addition, a 
smeared band was observed around 46 kDa. Heating of the sample and addition of 
PNGase F buffer caused a signal reduction of the higher molecular weight bands 
and the disappearance of the low molecular weight band which likely corresponds to 
a proteolytically cleaved form of B0AT1. 
Figure 12. Characterization of anti-B0AT1 and anti-TMEM27 antibodies. Cell lysates from 
HEK293T cells transfected with B0AT1 or TMEM27 were resolved with SDS-PAGE after treatment 
with (+) or without (-) Peptide-N-glycosidase F (PNGase F) enzyme. After Western blot protein 
transfer membranes were incubated with anti-B0AT1 (panel A) or anti-TMEM27 (panel B) antibodies. 
β-actin was used as loading control. * indicates samples which were neither heated nor incubated 
with PNGase F buffer.  
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Next, we tested commercial polyclonal antibodies raised in mouse against the 
full length of human TMEM27 sequence. Lysates from HEK293T cells transiently 
transfected with TMEM27 showed a specific signal in Western blot experiments 
when compared to the control lane (Fig. 12, panel B). In addition, PNGase F 
treatment showed a single band at ~27 kDa corresponding to the deglycosylated 
protein. 
 
4.2.2 Overexpression of B0AT1 and TMEM27 in MDCK cells using a lentiviral 
Tet-On system 
To better understand the interaction between B0AT1 and TMEM27, as well as 
the impact of the renal accessory protein on B0AT1 expression and stability, MDCK 
cells were chosen as in vitro model. Unfortunately, constitutive overexpression of 
B0AT1 and TMEM27 in MDCK cells was not tolerated by the cells. Transduced 
MDCK cells either lost their phenotype, not forming tight epithelia anymore, or the 
expression of the amino acid transporter and its accessory protein was rapidly lost 
within few passages (Lisa Ruckstuhl, Lisa Arps – unpublished data). To overcome 
this problem we used a KRAB repressor based inducible system. Doxycycline 
treatment demonstrated a significant induction of B
0
AT1 and TMEM27 protein 
expression after the first transduction, as shown by Western blot (Fig. 13, panel A) 
and immunofluorescence microscopy (Fig. 13, panel B) experiments. 
Figure 13. Inducible overexpression of B
0
AT1 and TMEM27 in MDCK cells. MDCK cells 
transduced with B
0
AT1 or TMEM27 were grown on plastic or on poly-D-lysine coated cover-slips in 
presence (+) or absence (-) of doxycycline. Western blot (panel A) and immunofluorescence 
microscopy (panel B) showed a significant induction of B
0
AT1 and TMEM27 protein in transduced 
cells.  
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Induction with doxycycline resulted in co-expression and co-localization of B
0
AT1 
and TMEM27 proteins in B
0
AT1-TMEM27 transduced MDCK cells, as detected by 
immunofluorescence microscopy (Fig. 14). 
Figure 14. Co-expression of B
0
AT1 and TMEM27 in MDCK cells. B
0
AT1-TMEM27 overexpressing 
MDCK cells were grown on poly-D-lysine coated cover-slips in presence (+) or absence (-) of 
doxycycline. Immunodetection of B
0
AT1 (red) and TMEM27 (green) in double transduced MDCK 
cells showed co-expression of both protein and a partial co-localization (orange). 
 
Since the obtained mixed populations showed a non homogenous expression of 
both gene products, we decided to generate clonal cell lines with the expectation 
that they would display a more uniform transgene expression. Therefore, the above 
described mixed population MDCK cell lines were subjected to a limited dilution. Six 
clones per each cell line were selected based on the mRNA expression of the 
transduced gene (data not shown). A second screening based on protein 
expression resulted in a reduced number of working clones. Three clones of each 
cell line expressing the protein alone and three clones of the cell line co-expressing 
the two proteins together were selected. Western blot results demonstrated that 
clonal cell lines have differences in level of B
0
AT1 and TMEM27 protein expression 
(Fig. 15, panel A). Unlike expected, immunofluorescence data showed that clonal 
cell lines co-expressing B
0
AT1 and TMEM27 do not present a uniform expression 
pattern of both gene products. In fact, individual cells express either B
0
AT1 or 
TMEM27 and only few cells co-express both proteins (Fig. 15, panel B). 
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Figure 15. Protein-based screening of B
0
AT1 and/or TMEM27 transduced MDCK clonal cell 
lines. B
0
AT1 and/or TMEM27 overexpressing MDCK clones were grown on plastic or on poly-D-
lysine coated cover-slips in presence (+) or absence (-) of doxycycline. Western blot (panel A) and 
immunofluorescence microscopy (panel B) showed different levels of B
0
AT1 and TMEM27 protein 
expression among the clones. Immunodetection of B
0
AT1 is shown in red, TMEM27 in green, 
whereas orange indicates co-localization. 
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4.2.3 Effect of TMEM27 on B0AT1 function 
To test if TMEM27 may impact on B0AT1 transport activity, functional studies 
were performed. Leucine transport was measured in MDCK cells grown on 
polycarbonate filters. Trans-epithelial resistance (TEER) of the monolayer was 
measured before the uptake experiment and MDCK clones formed a tight epithelium 
(TEER ≥ 1 kΩ·cm2) when grown on permeable supports. In addition, we observed 
significantly higher Na+-dependent uptake of B0AT1 substrate amino acid in cells co-
expressing B0AT1 and TMEM27 compared to the wild-type cells or cells expressing 
B0AT1 alone (Fig. 16). 
Figure 16. TMEM27 upregulates B0AT1 function in MDCK cells. Wild-type MDCK cells or clonal 
cell lines transduced with either B0AT1 or B0AT1 and TMEM27 were grown on permeable supports. 
The apical uptake of 1 mM L-leucine was measured for 10 min in presence of Na+. Data are 
represented as mean ± SEM of 3 biological replicates; * = p≤ 0.05, one-way ANOVA followed by 
Tukey’s post-test. 
 
4.2.4 Effect of TMEM27 on B0AT1 localization 
To understand whether the effect of TMEM27 on B0AT1 transport is caused by 
changes of B0AT1 surface expression, confocal immunofluorescence microscopy 
was performed on MDCK cells grown on filters. In absence of TMEM27, B0AT1 
showed predominantly cytosolic expression (Fig. 17, upper panel, left picture). In 
contrast, cells co-expressing B0AT1 and TMEM27 showed surface expression of 
both proteins (Fig. 17, lower panel). However few cells expressing B0AT1 alone 
showed surface localization of the amino acid transporter (Fig. 17, upper panel, right 
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picture). We hypothesized that the endogenous TMEM27 or ACE2 might play a role 
in the surface localization of B0AT1 in absence of the exogenous TMEM27. We 
therefore analyzed the endogenous expression of the two accessory proteins of 
B0AT1 by RT-PCR. Both TMEM27 and ACE2 canine mRNA expression could be 
detected in MDCK cells (Fig. 18). 
Figure 17. TMEM27 changes B0AT1 localization in MDCK cells. MDCK cells were grown on 
polycarbonate filters. Immunofluorescence staining followed by laser confocal scanning microscopy 
was performed on clonal MDCK cell lines expressing either only B0AT1 (upper panel) or co-
expressing B0AT1 and TMEM27 (lower panel). Co-localization of B0AT1 and TMEM27 is shown in 
yellow. 
Figure 18. MDCK cells endogenously express ACE2 and TMEM27 at the mRNA level. Reverse 
transcription PCR was performed with material from B0AT1 expressing MDCK cells. Data showed 
ACE2 and TMEM27 mRNA expression in MDCK cells. HPRT was used as control. 
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4.2.5 Does TMEM27 interact with B0AT1 in vitro? 
 TMEM27 has previously been shown to interact with B0AT1 in vivo (Danilczyk et 
al., 2006). To test the role of their interaction in vitro MDCK cells co-expressing 
B0AT1 and TMEM27 were used. Immunoprecipitation with anti-B0AT1 antibody 
followed by Western blotting using the same antibody demonstrated a successful 
immunoprecipitation of B0AT1 protein (Fig. 19). However, a low increase in B0AT1 
signal upon immunoprecipitation compared to the total abundance was observed 
(Fig. 19, see IP fraction versus total input in B0AT1 Western blot). In addition, anti-
TMEM27 antibody did not confirm the physical interaction in vitro. Under none of the 
tested conditions (high salt vs low salt buffer, more or less stringent detergents) co-
immunoprecipitation of TMEM27 with B0AT1 antibodies was possible (data not 
shown). 
Figure 19. TMEM27 it is not quantitatively co-immunoprecipitated with B0AT1 in MDCK cells. 
Clonal MDCK cells overexpressing B
0
AT1 and/or TMEM27 were grown on plastic in presence (+) or 
absence (-) of doxycycline. Cell lysates were incubated overnight with anti-B
0
AT1 antibodies. 
Immunoprecipitated complexes were analyzed by Western blotting using anti-B
0
AT1 and anti-
TMEM27 antibodies. Post-IP: not bound fraction; IP: immunoprecipitated fraction. 
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4.2.6 Effect of TMEM27 on B0AT1 protein stability 
To investigate the impact of TMEM27 co-expression on B0AT1 protein stability, 
we performed pulse-chase analysis followed by immunoprecipitation with anti-
B0AT1 antibody. Shortly after pulse, the core-glycosylated band of B0AT1 was 
detected at ~66 kDa in both, presence or absence of TMEM27 (Fig. 20). 
Importantly, during the chase period, B0AT1 was observed maturing to the fully 
glycosylated form of ~100 kDa. The fully glycosylated protein band was not clearly 
stabilized by TMEM27 co-expression. In addition, co-precipitation of TMEM27 with 
anti- B0AT1 antibody was not successful (data not shown). 
Figure 20. TMEM27 does not stabilize B0AT1 in MDCK cells. B0AT1 immunoprecipitation was 
performed on lysates of wild type (wt), B0AT1 or B0AT1 and TMEM27 overexpressing MDCK cell 
clones that were pulse-labelled for 1 h and chased for the number of hours indicated. Lower arrow 
indicates core-glycosylated B0AT1 whereas the upper one shows the fully-glycosylated B0AT1. 
 
 
Taken together, the data suggested that TMEM27 increases B0AT1 function by 
upregulating its surface expression. The physical interaction between the two 
proteins shown in vivo was not proven in vitro. Furthermore, it remains unclear 
whether TMEM27 regulates B0AT1 protein stability. 
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4.3 Discussion 
 B0AT1 is the main neutral amino acid transporter expressed on the apical 
membrane of renal proximal tubules and intestinal epithelial cells (Romeo et al., 
2006). Renal expression and function of B0AT1 have been shown to depend on the 
co-expression of TMEM27 (Danilczyk et al., 2006). The initial goal of this thesis was 
to characterize the cellular and molecular mechanisms underlying the interaction 
between B0AT1 and TMEM27 in vitro.  B0AT1-TMEM27 co-expression in MDCK 
cells confirmed the importance of TMEM27 for B0AT1 function. Also, we provided 
conclusive evidence that TMEM27 is an important regulator of B0AT1 trafficking, as 
TMEM27 expression is required for B0AT1 correct cell surface localization. 
 
4.3.1 B0AT1-TMEM27 overexpression in MDCK cells is inducible but not 
uniform 
 We generated MDCK cell lines overexpressing B0AT1 and/or TMEM27 under the 
control of an inducible promoter. This cell line of distal nephron origin represents a 
well-established model for epithelial polarity studies (Misfeldt et al., 1976; Cereijido 
et al., 1978). The choice of a conditional lentiviral system over the classical 
constitutive expression system was due to the hypothesis that the luminal neutral 
amino acid transporter overexpression could be toxic for the cells. In fact, several 
attempts performed by former students in our group resulted in changes in MDCK 
cell morphology and loss of B0AT1 expression along the cell culture passages 
(unpublished data). Mixed populations of MDCK cells transduced with KRAB-
B0AT1-TMEM27 showed a normal morphology and a considerable induction of the 
amino acid transporter and its accessory protein upon treatment with doxycycline. 
To obtain a more homogenous cell population, we isolated MDCK clonal cells which 
exhibited high levels of B0AT1-TMEM27 protein expression. In contrast to our 
expectations, B0AT1-TMEM27 overexpressing clonal cell lines did not show a 
uniform expression pattern of B0AT1 and TMEM27 proteins. More precisely, the 
gene product transduced in the first place was more expressed than the second 
one. Previous studies indicated that the transduction efficiency of a retroviral vector 
is dramatically decreased if the cells have been already transduced with another 
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retroviral vector (Walker et al., 1996). Thus, the viral interference could explain the 
weak co-expression of both transgenes in our MDCK cell model.  
  
4.3.2 TMEM27 increases B0AT1 function by upregulating its surface 
expression 
 Several amino acid transporters require accessory proteins for their correct 
localization on the plasma membrane and function. The best characterized 
examples are the heavy chains and the heterodimeric amino acid transporters 
(SLC3 and SLC7 family). The heavy chain rBAT (SLC3A1) interacts with the 
catalytic light chain b0,+AT (SLC7A9) to which it is linked by a disulphide bridge. 
Interestingly, rBAT has been shown to be necessary for the correct trafficking of the 
complex to the plasma membrane (Pfeiffer et al., 1999a). Likewise, CD98/4F2hc 
forms a physical complex with several SLC7 family members (namely LAT1, LAT2, 
y+LAT1, y+LAT2, xCT, ASC1 (SLC7A5, 8, 7, 6, 11 and 10, respectively)) and is 
required for their correct localization on the basolateral membrane of renal proximal 
tubular cells. However, a few other partner proteins have been suggested to have a 
negative interaction with amino acid transporters. For example, the Glutamate 
Transport Associated Protein for EAAT3 (SLC1A1) (GTRAP3-18) is known to 
downregulate EAAT3-mediated glutamate transport by delaying EAAT3 traffic from 
the ER to the Golgi (Ruggiero et al., 2008). Here, we showed that TMEM27 
increases B0AT1 function by upregulating its surface expression. In the absence of 
TMEM27, the heterologous B0AT1 was still expressed in MDCK cells but did not 
correctly traffic to the apical membrane of epithelial cells. However, few cells 
expressing B0AT1 in the absence of TMEM27 showed an apical localization of the 
amino acid transporter. We hypothesized that the canine TMEM27 and ACE2, 
shown to be expressed in MDCK cells at the mRNA level, might allow the delivery of 
B0AT1 to the luminal membrane in the absence of exogenous TMEM27. Taken 
together, our data confirmed that B0AT1 requires TMEM27 for a correct apical 
localization. 
 The cellular and molecular mechanisms underlying B0AT1 and TMEM27 
interaction are still unclear. In contrast to the published in vivo data (Danilczyk et al., 
2006), the present immunoprecipitation experiments did not show a direct binding 
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between B0AT1 and TMEM27 in vitro. The reason for this differential response is 
uncertain. The experimental conditions (ionic strength of the buffer, detergents, etc.) 
might have been not optimal for the co-immunoprecipitation, the sensitivity of the 
system not sufficient to reveal it or an additional partner protein stabilizing the 
interaction in vivo missing. The association between B0AT1 and TMEM27 has been 
already shown to occur through non-covalent interactions, as both proteins migrate 
with the same mobility, both under reducing and non-reducing conditions (Danilczyk 
et al., 2006). The difficulties encountered in co-immunoprecipitation of B0AT1 with 
TMEM27 suggest a low affinity or transient interaction between the two proteins. 
Interestingly, TMEM27 has been shown to bind to the N-ethylmaleimide-sensitive 
fusion attachment receptor (SNARE) complex proteins by directly interacting with 
the vesicular protein snapin in pancreatic β-cells (Fukui et al., 2005) and in renal 
collecting duct cells (Zhang et al., 2007; Yasuhara et al., 2008). This interaction has 
been suggested to be crucial for the exocytosis of insulin (Fukui et al., 2005) and 
vesicular trafficking of polycystin-2 (Zhang et al., 2007). Nevertheless, there is no 
clear evidence, with the exception of EAAC1 (Fournier and Robinson, 2006), that 
amino acid transporters trafficking is mediated by SNARE proteins. 
 It is still unclear whether B0AT1 protein stability is affected by TMEM27 co-
expression. In vivo data showed a dramatic decrease in B0AT1 protein expression in 
brush border membrane vesicles of TMEM27 null mice (Danilczyk et al., 2006). 
Similarly, ACE2 knock-out mice displayed lack of B0AT1 protein expression in the 
enterocytes (Camargo et al. 2009). These data suggested that B0AT1 is rapidly 
degraded in absence of its accessory proteins. Previous studies indicated that when 
overexpressed in the absence of the light chain b0,+AT, the heavy chain rBAT is 
rapidly degraded by the endoplasmic-reticulum-associated protein degradation 
(ERAD) pathway (Bartoccioni et al., 2008). In our study, pulse-chase analysis 
followed by immunoprecipitation with anti-B0AT1 antibodies showed that both in the 
presence and absence of exogenous TMEM27 B0AT1 is rapidly shifted to a 
terminally glycosylated form (Fig. 20). However, it is not possible to determine from 
our analysis whether this matured form of B0AT1 is stabilized by the co-expression 
with TMEM27. 
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 In summary, B0AT1-TMEM27 inducibly overexpressing MDCK cells displayed 
normal epithelial phenotype and significant induction of both transgenes. However, 
this cell model showed some disadvantages, such as the uneven co-expression of 
the transgenes, the endogenous expression of TMEM27 and ACE2 and the loss of 
both transgenes expression along cell culture passages (this phenomenon has been 
further discussed in the manuscript). Due to these limitations, the interpretation of 
results was not always straightforward. To date, there is unfortunately not a good 
model for studying amino acid transporters in proximal tubule cells. Several cell 
lines deriving from various species such as human (HK-2), opossum (OK) or porcine 
(LLC-PK1) have been established. However, they exhibit de-differentiation markers 
since they lose the proximal tubule cell-specific biochemical and transport 
properties. Similarly, primary tubule cells present several disadvantages such as the 
limitation of the cell source, high variability and de-differentiation under in vitro 
conditions. In conclusion, although B0AT1-TMEM27 overexpressing MDCK cells 
have a number of limitations, the ability to form polarized tight epithelia makes them 
a relevant cell model for the characterization of amino acid transporters trafficking 
and function. However, care must be taken when choosing the cell culture 
conditions and the overexpression system, as these parameters highly impact on 
the results.  
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Abstract 
Gene expression and cell growth rely on the intracellular concentration of amino acids that 
in metazoans depends on extracellular amino acid availability and transmembrane 
transport. To investigate the impact of extracellular amino acid concentrations on the 
expression of a concentrative amino acid transporter, we overexpressed the main kidney 
proximal tubule luminal neutral amino acid transporter B0AT1-collectrin (SLC6A19-
TMEM27) in MDCK cell epithelia. Exogenously expressed proteins co-localized at the 
luminal membrane and mediated neutral amino acid uptake. However, the transgenes were 
lost over few cell culture passages. In contrast, the expression of a control transgene 
remained stable. To test whether this loss was due to inappropriately high amino acid 
uptake, freshly transduced MDCK cell lines were cultivated either with physiological 
amounts of amino acids or with the high concentration found in standard cell culture media. 
Expression of exogenous transporters was unaffected by physiological amino acid 
concentration in the media. Interestingly, mycoplasma infection resulted in a significant 
increase in transgene expression and correlated with the rapid metabolism of L-arginine. 
However, L-arginine metabolites were shown to play no role in transgene expression. In 
contrast, activation of the GCN2 pathway revealed by an increase in eIF2α phosphorylation 
may trigger transgene derepression. Taken together, high extracellular amino acid 
concentration provided by cell culture media appears to inhibit the constitutive expression of 
concentrative amino acid transporters whereas L-arginine depletion by mycoplasma 
induces the expression of transgenes possibly via stimulation of the GCN2 pathway. 
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Introduction 
Mammals have developed a finely tuned response to changes in nutrient availability. Amino 
acid sufficiency activates the mammalian target of rapamycin (mTOR) pathway, which 
ultimately promotes protein synthesis and cell growth. In contrast, amino acid limitation 
initiates an amino acid response (AAR) signaling cascade, which regulates multiple steps in 
gene expression including chromatin structure modification, transcription and translation [1]. 
Individual cells sense amino acid deficiency through an accumulation of uncharged tRNAs 
which bind to and activate the GCN2 protein kinase [2–4]. GCN2 protein kinase 
phosphorylates and inactivates the eukaryotic initiation factor 2α (eIF2α), which in turn 
leads to a decrease of global mRNA translation [4,5]. To compensate for this restriction, the 
expression of a spectrum of genes involved in the adaptive response to nutritional stress is 
stimulated. This phenomenon, known as translational derepression, was first described for 
the yeast transcription factor GCN4 [6], and then shown for the mammalian GCN4 
homologue, activating transcription factor 4 (ATF4) [7]. ATF4 binds to C/EBP-ATF response 
elements (CARE)-containing genes and triggers their transcription. Among the genes 
induced by amino acid limitation, amino acid transporters (SLC7A1, SLC38A2), transcription 
factors (CHOP) or amino acid metabolic enzymes (ASNS) have been identified (reviewed in 
Ref. [1]). 
The transport of amino acids across epithelial cells is mediated by a wide array of 
membrane proteins. Previously, to investigate the role of specific amino acid transporters, 
we reconstructed the transepithelial exchange of L-Arg and L-Leu by expressing the luminal 
heterodimeric amino acid antiporter b0,+-rBAT (SLC7A9-SLC3A1) and the basolateral 
heterodimeric antiporters y+LAT1-4F2hc (SLC7A7-SLC3A2) and LAT2-4F2hc (SLC7A8-
SLC3A2) in MDCK epithelial cells [8,9]. This cell line of distal nephron origin represents a 
well-established model for epithelial polarity studies [10,11]. The overall directional 
(re)absorptive transport of amino acids is however driven by accumulative transporters 
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located in the luminal membrane of transporting epithelia. In the proximal kidney tubule and 
in the small intestine, this central role is mainly played by the luminal sodium symporter for 
neutral amino acids B0AT1 (SLC6A19) [12,13]. Mutations in its gene have been shown to 
cause autosomal recessive Hartnup disorder [14,15]. The expression and function of B0AT1 
depends on the co-expression of members of the renin angiotensin system (RAS), namely 
TMEM27 (collectrin) in the kidney proximal tubule and angiotensin converting enzyme 2 
(ACE2) in the small intestine [16,17]. Apart from dependence on organ-specific accessory 
proteins and recent data on the transcriptional control of its expression along the crypt-villus 
axis [18], the mechanisms controlling B0AT1 expression and function are largely unknown. 
Mycoplasma infection represents a well-known and insidious problem for cell culture users. 
Mycoplasmas are small bacteria (0.3-0.8 µm in diameter) which lack a cell wall and are not 
susceptible to many usual antibiotics. The major source of mycoplasma contamination in 
cell culture is the laboratory personnel, as the non-pathogenic mycoplasma (such as M. 
orale) colonize the oral cavity of humans and can easily spread to the laboratory equipment, 
media and reagents [19]. The effects of mycoplasma infections on the contaminated cell 
lines are variable and depend on the degree of infection. Previous studies have shown that 
mycoplasma use arginine as their major source of energy, converting it to ornithine and 
thereby producing adenosine triphosphate through a complex set of reactions [20]. The lack 
of an essential amino acid from the cell culture medium induces biochemical changes in the 
host-cell metabolism, which ultimately lead to a decrease in cell growth and cell death [21]. 
Since amino acid availability has been shown to affect the expression and activity of several 
amino acid transporters [22–24], the initial goal of the present study was to investigate the 
effect of extracellular amino acid availability on B0AT1 expression, in particular at post-
transcriptional levels. To construct an appropriate in vitro proximal tubule model, we co-
expressed B0AT1 with its renal accessory protein TMEM27 (B0AT1-TMEM27) in MDCK cell 
epithelia under the control of the heterologous cytomegalovirus (CMV) promoter. Unlike for 
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the exogenous expression of antiporters previously mentioned, expression of B0AT1-
TMEM27 was unstable and inhibited by high extracellular amino acid concentrations. 
Furthermore, mycoplasma infection of MDCK cells increased expression of all tested 
exogenously expressed genes presumably via stimulation of the GCN2 pathway.  
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Materials and Methods 
Cell culture 
MDCK cells, kindly provided by Dr. N. Simmons (Newcastle University), were cultured at 
37°C and 5% CO2 in DMEM (catalog no. E15-810, GE Healthcare, Glattbrugg, Switzerland) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, Buchs, 
Switzerland), 2 mM L-glutamine and 1% non essential amino acids (catalog no. M11-003, 
GE Healthcare). 
Phoenix amphotropic retrovirus producer cells, kindly provided by Dr. G. Nolan (Stanford 
University), were cultured at 37°C and 5% CO2 in DMEM (catalog no. E15-843, GE 
Healthcare) supplemented with 10% heat-inactivated FBS (Sigma-Aldrich), 2 mM 
L-glutamine and 1% non essential amino acids. 
Human embryonic kidney cells (HEK293T), kindly provided by Dr. D. Schümperli (University 
of Bern) were grown in DMEM (catalog no. E15-810, GE Healthcare) supplemented with 
10% heat-inactivated FBS (Sigma-Aldrich), 2 mM L-Glutamine and 1% non essential amino 
acids at standard cell culture conditions (37°C, 95% relative humidity and 5% CO2). 
 
Mycoplasma detection by PCR analysis 
Mycoplasma infection in cell cultures was detected using Venor®GeM (Minerva biolabs, 
Berlin, Germany) following the manufacturer’s instructions. 2 µL of medium deriving from 
confluent cell cultures were used for each PCR reaction.  
 
Reagents 
Physiological medium and arginine-free medium consisted of an amino acid-free DMEM 
(modified E15-810, custom-made GE Healthcare) supplemented with 5% FBS and 
physiological amino acid (1x PAA) concentrations or cell culture amino acid (except for 
arginine) concentrations, respectively, pH adjusted to 7.4, as listed in Table 1. Cell culture 
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tested amino acids, polyamines and urea (Sigma-Aldrich) were dissolved in Hanks’ buffered 
salt solution (HBSS; GE Healthcare) in stock solutions of 10, 50 or 100 mM. 
 
Cell treatments 
Unless specified otherwise, MDCK cells (below passage 10) were seeded at confluent 
density (1.7·105 cells/cm2) and cultivated on Corning Costar Transwell filters (Corning, 
Amsterdam, The Netherlands) for 6 days in DMEM supplemented with 5% FBS, 2 mM L-
glutamine and 1% non essential amino acids. In time course experiments with physiological 
levels of amino acids, cells were grown in regular DMEM and then treated for the last 1, 3 or 
5 days of culture with 1x PAA medium. Cells were grown in regular DMEM for the first 3 
days and then treated for 3 additional days with: 1) amino acid-free medium supplemented 
with 0.5-8.0x PAA concentrations (dose response experiments); 2) amino acid-free medium 
supplemented with the tested amino acids at 8x PAA levels and the remaining amino acids 
at 0.5x PAA concentrations (substrate specificity experiments). Cells were grown in 
arginine-free medium supplemented with 180 μM arginine for the first 3 days and then 
treated for 3 additional days with: 1) arginine-free medium supplemented with 45, 180 or 
720 μM arginine (arginine time course experiments); 2) arginine-free medium supplemented 
with 720 μM arginine and NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 0-2000 
μM; Sigma-Aldrich), arginase inhibitor Nw-Hydroxy-nor-L-arginine (nor-NOHA, 0-500 μM; 
Millipore, Zug, Switzerland) or α-difluoromethylornithine (DFMO, 0-3 mM; Sigma-Aldrich) 
(inhibitor experiments); 3) arginine-free medium supplemented with 45 μM L-arginine in the 
presence or absence of 675 μM citrulline, ornithine, urea, D-arginine, or 10 μM putresceine, 
spermidine, spermine, or NO donor sodium nitroprusside (SNP, 0-10 μM; Sigma-Aldrich) 
(metabolite experiments); 4) arginine-free medium supplemented with 720 μM arginine and 
HDAC inhibitor trichostatin A (TSA, 1 μM; Sigma-Aldrich). 
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cDNA constructs, transfection, and viral transduction 
The human B0AT1 cDNA sequence was inserted in the multiple cloning site of pIRES2-
EGFP (catalog no. 6029-1, Life Technologies, Zug, Switzerland), upstream of the internal 
ribosomal entry site and the EGFP reporter gene. Human TMEM27 cDNA sequence was 
then subcloned in the above mentioned vector in place of EGFP sequence. The resulting 
bicistronic construct containing B0AT1 and TMEM27 upstream and downstream of IRES, 
respectively, was then excised from the plasmid and inserted in the retroviral vector pLPCX 
(Clontech, Saint-Germain-en-Laye, France). EGFP was introduced in pLPCX as previously 
described [25]. Production of supernatants containing the pseudoviruses and subsequent 
transduction of MDCK target cells was performed as previously described [9]. The first 
subcultivation after transduction was defined as passage 1. Stable MDCK cell lines were 
selected and maintained in standard growth DMEM containing 2 µg/mL puromycin (Sigma-
Aldrich). Human TMEM27 cDNA sequence was subcloned as a PCR fragment flanked by 
SmaI and XhoI restriction sites into the Eco47III and XhoI sites of pLenti6-EGFP (Life 
Technologies), thus yielding to pLenti6-TMEM27 vector. Lentiviral production was 
performed according to the protocol described elsewhere [26]. Infected MDCK cells were 
selected with 6 µg/mL blasticidin S (Life Technologies). 
 
Antibodies 
Polyclonal rabbit antibodies were raised against the synthetic peptide NH2-
NPGLDARIPSLAELEC-CONH2 of human B0AT1 and further affinity purified (Pineda, Berlin, 
Germany). Mouse anti-TMEM27 (Abnova, Taipei, Taiwan), mouse anti-EGFP (Clontech), 
rabbit anti-4E-BP1 (Cell Signaling, Danvers, MA, United States), rabbit anti-phospho-4E-
BP1 (Thr70) (Cell Signaling), rabbit anti-eIF2α (Cell Signaling), rabbit anti-phospho-eIF2α 
(Ser51) (Cell Signaling), rabbit anti-ZO-1 (Life Technologies) and mouse anti-β-actin 
(Sigma-Aldrich) were used according to the manufacturers’ instructions. Horse radish 
5. MANUSCRIPT 
59 
 
peroxidase goat anti-rabbit IgG and alkaline phosphatase goat anti-mouse IgG secondary 
antibodies were purchased from Promega (Dübendorf, Switzerland).  
 
Immunofluorescence staining of MDCK cells 
MDCK cells on filters were washed twice with cold phosphate-buffered saline (PBS) 
supplemented with 1 mM MgCl2 and 100 µM CaCl2 (PBS++) and fixed for 5 min in 
methanol:acetone (1:1) at -20°C. Filters were washed three times in PBS++ and nonspecific 
binding sites were blocked for 30 min at room temperature with 2% bovine serum albumin 
(BSA, Sigma Aldrich) in PBS++ supplemented with 0.1% Triton X-100 (Sigma Aldrich). Cells 
were incubated overnight with primary antibody to anti-B0AT1, anti-TMEM27 or anti ZO-1 as 
indicated, diluted in 2% BSA in PBS++ supplemented with 0.1% Triton X-100. After washing, 
cells were incubated for 1 h at room temperature with Alexa Fluor 594 anti-rabbit-IgG 
antibody (Life Technologies) and Alexa Fluor 488 anti-mouse IgG antibody (Life 
Technologies). 4’,6-Diamidino-2-Phenylindole Dihydrochloride (DAPI, Life Technologies) 
was added to the secondary antibody mix in order to counterstain the nuclei. Filter pieces 
were mounted in DAKO-Glycergel (Dako, Baar, Switzerland) and analyzed with a Leica 
TCS SP5 confocal laser scanning microscope (Leica, Heerbrugg, Switzerland) using a 63x 
objective lens (Leica). Digital images were processed using the software Imaris (Bitplane, 
Zurich, Switzerland), 
 
Amino acid uptake 
MDCK cells were grown on filters and the trans-epithelial electrical resistance across intact 
monolayers was measured using EVOHM device (World Precision Instruments, Sarasota, 
FL). Amino acid uptake was performed as previously described [9]. Briefly, cells were 
washed three times and then incubated for 30 min at 37°C with uptake buffer (150 mM 
NaCl, 10 mM HEPES pH 7.4, 1 mM CaCl2, 5 mM KCl, 1 mM MgCl2, 10 mM glucose). Fresh 
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uptake buffer was then applied on the basolateral side whereas the apical compartment 
received the uptake buffer supplemented with 1 mM L-Leucine and the corresponding 3H-
labeled L-Leucine (Hartmann Analytic, Braunschweig, Germany) as tracer. 14C-labeled 
mannitol (Hartmann Analytic) was used as a control for the integrity of the cell monolayer. 
After 10 min incubation at 37°C, the uptake was stopped by replacing the apical and 
basolateral solutions with ice-cold uptake buffer. The cells were washed three times and the 
filters were excised and placed into scintillation fluid and shaked overnight at room 
temperature. Radioactivity was measured by liquid scintillation analyzer (Packard Tri-Carb 
2900TR, PerkinElmer, Schwerzenbach, Switzerland). 
 
Western blotting 
Cells were lysed with ice-cold Radio-Immunoprecipitation Assay (RIPA) buffer (150 mM 
NaCl, 50 mM Tris pH 7.4, 1% NP-40, 0.5% Na-Deoxycholate) supplemented with fresh 
Protease Inhibitor Cocktail (Sigma) and PhosSTOP (Roche, Rotkreuz, Switzerland) and 
incubated for 40 min on ice. Cellular debris was pelleted with centrifugation at 2500 g for 
10 min at 4°C and the protein concentration was determined by DC-Protein Assay, following 
the manufacturer’s guidelines (Bio-Rad, Cressier, Switzerland). Cell extracts (20-40 µg 
protein) were resolved by SDS-PAGE on 10 or 12% gels and electrophoretically transferred 
to PVDF membranes (Immobilion-P, Millipore). Nonspecific binding sites were blocked for 
1 h at room temperature with 5% powdered milk in Tris-buffered saline supplemented with 
0.1% Tween-20 (TBS-T). Blots were then incubated overnight at 4°C with the primary 
antibody diluted in 5% powdered milk in TBS-T. After washing the blots with TBS-T, 
secondary antibody diluted in 5% powdered milk in TBS-T was applied for 1 h at room 
temperature and the antibody binding was detected with Immobilion Western 
Chemiluminescent HRP substrate (Millipore) or CDP-Star (Roche) and visualized with 
FujiFilm Las-4000 camera (GE-Healthcare) according to the manufacturer’s instructions. 
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Image-J software (National Institutes of Health, Bethesda, MD) was used for densitometric 
analysis of the Western blots. 
 
RT-PCR 
Total RNA from cell pellet was isolated using RNeasy Mini Kit (Qiagen, Basel, Switzerland) 
following the manufacturer’s instructions. Reverse transcription of the isolated RNA was 
performed with TaqMan® RT Kit using random hexamers (Life Technologies). Gene 
expression was quantified by quantitative real-time PCR using Taq Ready MixTM (Life 
Technologies) as previously described [12]. Primers and probes are listed in Table 2. 
Probes were labelled with the reporter dye FAM at the 5' end and the quencher dye TAMRA 
at the 3' end (Microsynth, Balgach, Switzerland). β-Actin or 18S (Life Technologies) were 
used as housekeeping genes. 
 
Amino acid measurements 
Media were collected from MDCK cells grown on filters. Briefly, deproteinized samples were 
derivatized using EZ:faastTM kit (Phenomenex, Torrance, CA) and further analyzed by 
LC-MS/MS using API Sciex 2000 instrument (Ab Sciex, Brugg, Switzerland). 
 
Cell count 
Cell nuclei were visualized using 4’,6-Diamidino-2-Phenylindole Dihydrochloride (DAPI, Life 
Technologies) and quantified using Image J software (National Institute of Health, USA). 
Briefly, the color image (RGB) was converted to grayscale (8-bit) and the threshold was 
adjusted. Watershed function was used to divide particles which had merged together. 
Nuclei were then counted, setting the size (pizel^2) between 400 and 3000 and circularity 
as default (0.00-1.00). The number of counted particles was then corrected for the area of 
the filter using Microsoft Excel Software. 
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Statistical analysis 
All experiments were carried out in at least 3 independent replicates. Data are expressed as 
mean ± SEM. Analysis of the experimental data was performed by GraphPad Prism 5.0.  
5. MANUSCRIPT 
63 
 
Results 
Co-expressed exogenous B0AT1 and TMEM27 localize to the luminal membrane of MDCK 
cells 
To investigate the impact of amino acids on the expression of the major renal proximal 
tubule luminal sodium-neutral amino acid symporter B0AT1-TMEM27, we established 
MDCK cells overexpressing both transporter subunits using a retroviral system. Such an in 
vitro system was successfully employed for previous studies on overexpressed luminal 
amino acid antiporter b0,+AT-rBAT (SLC7A9-SLC3A1) and basolateral y+LAT1-4F2hc 
(SLC7A7-SLC3A2) and LAT2-4F2hc (SLC7A8-SLC3A2) [8,9]. Immunofluorescence studies 
on polarized MDCK cells showed an apical co-localization of B0AT1 and TMEM27 when co-
expressed (Fig. 1A). Consistent with previous observations in other expression systems 
[16], TMEM27 co-expression increases B0AT1 transport function also at the luminal surface 
of cultured MDCK cell epithelia (Fig. 1B).  
 
Expression of exogenous B0AT1 and TMEM27 is prevented by high amino acid content of 
cell culture medium and regulated upon mycoplasma infection 
As previously observed in various attempts to (over)express B0AT1 and TMEM27 in MDCK 
cells (data not shown), the expression of B0AT1 and TMEM27 proteins strongly decreased 
following subsequent cell culture passages (Fig. 1C and 1D). This effect was specific for the 
amino acid transporter and its accessory protein as the control cell line overexpressing 
EGFP did show a less significant change in protein expression. We speculated that in the 
elevated extracellular amino acid concentrations in standard cell culture medium the 
concentrative transporter B0AT1 increases intracellular amino acids concentrations. 
Increased intracellular levels exert a negative feedback on the activity and/or expression of 
the transporter, resulting in its downregulation. To test this hypothesis, freshly transduced 
B0AT1-TMEM27 overexpressing MDCK cell lines were subcultured on plastic dishes in low 
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amino acids containing media (so called physiological medium) or in control media 
(classical DMEM) and transgene protein expression was assessed by Western blotting. 
Unexpectedly, physiological amino acid containing medium did not significantly increase 
B0AT1-TMEM27 expression after 10 passages (Fig. S1). To test the effect of amino acid 
concentrations on polarized epithelia, B0AT1-TMEM27 overexpressing MDCK cell lines 
were cultivated on filters in physiological or standard cell culture medium and transgene 
mRNA and protein expression was assessed by quantitative PCR and Western blotting, 
respectively. When comparing various B0AT1-TMEM27 overexpressing MDCK cell lines 
under otherwise identical experimental conditions, we observed considerable variations in 
the response to physiological medium. PCR-based test for the presence of mycoplasma 
revealed an infection of these cell lines (data not shown) explaining their observed 
phenotypic change. Interestingly, B0AT1-TMEM27 overexpressing mycoplasma-infected 
MDCK cells cultured in low amino acid media reproducibly demonstrated a rapid time-
dependent increase of transgene mRNA (Fig. 2A and 2B) and protein expression (Fig. 2C 
and 2D), with a peak at three days. However, this effect of culture in low amino acid media 
was not specific for B0AT1-TMEM27 expression. Indeed, mycoplasma-infected MDCK cell 
lines overexpressing EGFP or TMEM27 in the absence of B0AT1 displayed a similar 
upregulation of transgene mRNA expression in low amino acid medium (Fig. S1). In 
contrast, the mRNA expression of endogenous housekeeping genes such as GAPDH and 
β-actin was unaffected (data not shown). Taken together, these results suggested that in 
low amino acid medium mycoplasma infection upregulates mRNA and protein expression of 
transgenes in MDCK cells. 
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Mycoplasma-mediated L-arginine depletion stimulates exogenous B0AT1 and TMEM27 
expression 
Next, we evaluated the dose response effect of media amino acids on transgene expression 
in mycoplasma-infected B0AT1-TMEM27 overexpressing MDCK cells. Western blotting 
analysis of protein samples prepared from cells cultured in different amino acid 
concentrations revealed a dose-dependent effect on B0AT1 expression (Fig. 3A).  
To identify whether a specific amino acid was responsible for the observed transgene 
upregulation, we divided the 20 proteinogenic amino acids into four groups and tested their 
effect on B0AT1 expression. Western blotting experiments showed that elevated essential 
amino acids alone were able to reduce B0AT1 protein expression as strongly as the control 
media (8-fold plasma amino acid concentrations which is similar to standard culture 
medium). In contrast, none of the other amino acid groups affected B0AT1 protein 
abundance (Fig. 3B). Therefore, the five essential amino acids of the group were tested 
individually. Only arginine, of the tested amino acids, significantly regulated B0AT1 protein 
abundance (Fig. 3C). These data showed that in mycoplasma-infected MDCK epithelia 
transgene upregulation by low amino acid media is dose dependent and suggested a 
pivotal role for arginine. 
To investigate the specific role of arginine on transgene expression, time course and dose 
response experiments were performed (Fig. 4). Quantitative PCR analysis showed that low 
arginine concentration drastically increases B0AT1 mRNA expression in a time-dependent 
manner (Fig. 4A), whereas transgene mRNA expression was inhibited by high arginine 
concentrations. Likewise but to a lesser extent, B0AT1 protein abundance was also 
regulated by low arginine concentrations in a time-dependent manner (Fig. 4B and 4C). 
Thus, these data indicated that in mycoplasma-infected MDCK cells low arginine levels 
increase both transgene mRNA and protein expression. 
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Transgene expression is not regulated by mammalian arginine metabolism 
The arginine effect on transgene expression appeared to have a relatively slow time course, 
suggesting the possibility that amino acid metabolism plays a critical role. We analyzed the 
amino acid concentration in the media of mycoplasma-infected MDCK cells cultured in low 
and high arginine media. Our data showed that arginine was indeed depleted from the 
medium within 24 h when initially administered at low concentration (Fig. 5A). Even when 
given at high concentration arginine metabolism led to its depletion within 48 h. This 
increased amino acid metabolism was arginine-specific as all other amino acids were not 
significantly decreased in the medium after 48 h (data not shown). Arginine consumption 
rate was correlated with ornithine production (Fig. 5B). Citrulline was also measured but its 
concentration was below the detection limits (<10 µM) at all the time points, except for the 
48 h (7.1±3.9 µM in low arginine medium and 13.1±1.7 µM in high arginine medium). 
Next, we tested whether inhibitors of mammalian arginine metabolizing enzymes, in 
particular of arginase, nitric oxide synthase and ornithine decarboxylase impact on B0AT1 
expression (see Fig. 6A for pathways). The fact that none of the tested drugs had an effect 
on B0AT1 protein expression suggested that their products are not involved in the observed 
transgene regulation (Fig. 6 B-D). Consistent with this observation, incubation of the 
transduced MDCK cells with high doses of ornithine, urea, polyamines, citrulline or a NO 
donor also did not affect transgene expression (Fig. 6E and 6F). Furthermore, the effect on 
transgene expression seemed to be specific for L-arginine, as D-arginine did not exert any 
effect (Fig. 6E). Thus, these results suggested that the observed transgene upregulation 
was not mediated by products of L-arginine metabolism but by the lack of L-arginine. 
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GCN2 pathway is activated by low arginine levels in mycoplasma-infected MDCK cells 
Recent studies have shown that transgene expression is regulated by low levels of 
essential amino acid such as Tyr and Met/Cys which trigger a downregulation of the histone 
deacetylase 4 (HDAC4) [27]. Indeed, inhibition of HDAC activity by trichostatin A (TSA) also 
upregulated the protein expression of B0AT1 (Fig. 7A). However, the mRNA expression of 
HDAC 4 as well as that of others HDACs (2, 3, 5, 6, 8, 10 and 11) was not regulated by a 
decrease in arginine concentration (data not shown). 
AA availability is known to be sensed by mTOR and the GCN2 pathway. To investigate 
whether mycoplasma-induced arginine depletion results in the regulation of one of these 
two pathways, the phosphorylation of their downstream effectors 4EBP-1 and eIF2α, 
respectively, was measured by Western blotting. While the phosphorylation of the mTOR 
downstream effector 4EBP-1 was unaffected by low arginine levels (Fig. 8A and 8B), the 
phosphorylation of the GCN2 effector eIF2α was rapidly increased after 4 h of incubation in 
low arginine medium (Fig. 8C and 8D). Interestingly, in the presence of high arginine 
medium eIF2α phosphorylation was also increased, but with a much slower time course. 
Taken together, these data showed that mycoplasma infection of MDCK cell cultures 
causes a rapid L-arginine depletion, which in turn activates the GCN2 pathway. 
 
Mycoplasma-induced arginine depletion affects MDCK cell number and tight epithelium 
formation  
The GCN2 pathway activation leads to a global decrease in protein synthesis, which in turn 
affects several vital processes such as proliferation, differentiation and apoptosis [5]. 
Indeed, mycoplasma-infected MDCK wild type cells showed a 20% reduction in cell number 
after 24 h culture in low arginine medium (Fig. 8A). In contrast, cells cultured in high 
arginine medium showed a progressive increase in cell number within 72 h. We also found 
that mycoplasma-infected MDCK cells cultivated on porous filters with low arginine medium 
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presented low trans-epithelial electrical resistance (TEER) during the time of culture (Fig. 
8B). In contrast, MDCK cells cultured in high arginine medium showed an increase in TEER 
over time, compatible with the formation of epithelial tight junctions. To determine if the 
effect of arginine on trans-epithelial electrical resistance was due to the regulation of tight 
junction proteins expression, we performed immunofluorescence staining of ZO-1, a 
classical component of tight junctions [28]. Our data clearly showed that mycoplasma-
infected MDCK cells initially had a low expression of ZO-1 at the tight junctions when 
treated with low arginine medium (Fig. 8C, t=24h). Nevertheless, both arginine treatments 
resulted in comparable ZO-1 protein abundance at the end of the cell culture (Fig. 8C, 
t=72h), suggesting that low arginine medium retards but does not fully prevent tight junction 
formation. These results showed that arginine deprivation dramatically affects MDCK 
epithelia, resulting in a decrease in cell number and TEER, which in turn corresponds to a 
delay in tight junction formation. 
5. MANUSCRIPT 
69 
 
Discussion 
The aim of this study was to characterize the impact of amino acids on the expression of the 
neutral amino acid transporter B0AT1 and its accessory protein TMEM27 in MDCK cells. 
The rationale for this study was based on the observation that B0AT1-TMEM27 
overexpressing MDCK cells displayed progressively reduced transgene expression after 
only a few culture passages. Interestingly, infection of MDCK cells with mycoplasma led to a 
rapid arginine depletion, which in turn triggered the derepression of silenced transgenes, 
most likely through the activation of the GCN2 pathway. These findings expand the 
biochemical changes induced by mycoplasma to the metabolism of infected cells by adding 
the novel role for arginine in the control of transgene expression [21]. Transgene silencing 
represents a common defense mechanism of mammalian cells, which identify the foreign 
sequences as cellular invaders and target them for silencing. Recent studies have shown 
that limitation of essential amino acids such as Tyr or Met/Cys regulates transgene 
expression in mammalian cells [27]. Here, we show that another (conditionally) essential 
amino acid, namely arginine can affect transgene expression. However, these results are in 
variance with those of Palmisano et al. [27], who suggested that the transgene regulation is 
a process involving inactivation or downregulation of the histone deacetylase 4 (HDAC4). 
Although both studies agree that amino acid deprivation activates a general response able 
to derepress integrated transgenes, we could not confirm the regulation of the transgene by 
histone deacetylases. Instead, the decrease of arginine in the medium was correlated with 
an increase in eIF2α phosphorylation after 4 h, which suggests that the transgene 
regulation is mediated by the activation of the GCN2 pathway. The amino acid response 
induced by amino acid deprivation is known to regulate gene expression at many steps, 
from the chromatin structure to the transcription and translation rates [1,29]. However, the 
mechanism which controls chromatin structure remodeling in response to amino acid 
deprivation is not yet understood [1]. Interestingly, the expression of several genes 
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encoding transcription factors has been shown to be increased by amino acid limitation. 
Examples include members of the activating transcription factor (ATF) family, FOS/JUN 
family, CCAAT/enhancer binding protein (C/EBP) family, and other transcription factors 
outside of the bZIP superfamily (reviewed in Ref. [30]). To date, there are no known 
transcription factors that increase the CMV promoter transcription rate resulting in an 
increase of the mRNA expression of transgenes. Instead, luciferase constructs driven by 
CMV promoter have been shown to be unaffected by amino acid deprivation in skeletal 
muscle cells [31].  
 
In the present study, inhibition of mammalian arginase, nitric oxide synthase and ornithine 
decarboxylase did not affect the transgene expression in MDCK cells. The rapid and 
massive breakdown of arginine to ornithine in MDCK cells is consistent with the time course 
previously observed in HeLa cells infected with mycoplasma [20]. Furthermore, arginine 
deiminase, the first mycoplasma enzyme involved in arginine breakdown, has a much 
higher arginine affinity (Km ~ 30 µM) than mammalian arginases (Km ~ 45 mM) [32]. Thus, 
although arginase activity of the cell line could account for some ornithine production, it is 
unlikely that the observed arginine degradation is an intrinsic feature of MDCK cells, but 
more likely it is an effect of mycoplasma infection. Given that the reaction which converts 
arginine to ornithine has a stoichiometry of 1, it was surprising to observe that ornithine 
concentration in the low arginine medium exceeded by far the expected concentration. It is 
possible that part of measured ornithine derives from the metabolism of glutamine and 
glutamate, which are present at approximately 6 mM in the cell culture medium. 
 
In addition to the effect on transgene expression, we found that mycoplasma-induced 
arginine depletion has an overall impact on MDCK epithelium formation. The reduction in 
MDCK cell number is consistent with previous studies which showed that deprivation of 
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essential amino acids from the cell culture medium (including arginine) triggers cell death 
[33,34]. Interestingly, cells treated with high arginine concentrations increased in cell 
number. However, the phosphorylation of 4E-BP1 protein was not affected by arginine 
levels in the media, suggesting that the mTOR pathway does not respond to arginine under 
the tested conditions in MDCK cells. These findings differ from previous studies which 
showed that arginine regulates the mTOR effectors in intestinal cells [35,36]. This is either 
due to a cell line difference or to the arginine concentration that we used, which might not 
have been sufficient to trigger the signaling pathway. Furthermore, we measured 
surprisingly low values of TEER in cells cultivated with low arginine medium. This might be 
a direct consequence of the lower cell number or of maturational changes in tight junction 
proteins. 
 
Taken together, we propose that the lack of arginine induced by mycoplasma infection is 
sensed by MDCK cells and triggers GCN2 pathway activation, which in turn results in 
exogenous gene reactivation. The proposed GCN2-dependent mechanism responsible for 
the derepression of silenced transgenes opens the door to new approaches aiming at 
improving viral-mediated gene therapy strategies for the treatment of genetic disorders and 
acquired diseases. 
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Figures 
 
Figure 1. Overexpression of B0AT1 and TMEM27 in MDCK cells. A: 
immunofluorescence analysis of B0AT1-TMEM27 overexpressing MDCK cells. Apical co-
localization (yellow) of B0AT1 (red) and TMEM27 (green) is visualized by confocal 
microscopy. Upper panels represent images taken parallel to the filter (x-y plane); lower 
panels show corresponding z-x reconstitutions. Bars = 5 µm. B: Apical uptake of L-Leu 
(100 µM, 10 min) in wild type (wt) or B0AT1 or B0AT1-TMEM27 overexpressing MDCK cells 
cultivated on filters. Data are represented as mean ± SEM (n=3). Groups were compared by 
one-way ANOVA followed by Tukey post-test; * p≤ 0.05. C: MDCK cells overexpressing 
B0AT1-TMEM27 or EGFP. After viral transduction, cells were subcultured on plastic dishes 
for 5 or 10 times (passage 5 and 10, respectively) in standard cell culture medium. Western 
blotting experiments with antibodies directed against B0AT1, TMEM27 and EGFP were 
performed. Representative Western blotting images are shown. 
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Figure 2. Effect of physiological amino acid levels on transgenes expression. Cells 
were cultivated on filters in standard cell culture medium and treated for the indicated times 
with physiological medium. A-B: mRNA expression of B0AT1 (A) or TMEM27 (B) was 
measured by quantitative PCR-analysis in B0AT1-TMEM27 overexpressing MDCK cells 
which were found Mycoplasma-free (open bar) or mycoplasma-infected (black bar). mRNA 
levels were standardized to β-actin and normalized to time 0. C-D: Western blotting 
experiments with antibodies directed against B0AT1 (C) or TMEM27 (D) were performed in 
mycoplasma-infected B0AT1-TMEM27 overexpressing MDCK cells and the intensity of the 
immunoreactive bands was quantified, standardized to β-actin and normalized to time 0. 
Representative Western blotting images are shown. Data are represented as mean ± SEM 
(n=3). Groups were compared by one-way ANOVA followed by Dunnett post-test; 
** p≤ 0.01, * p≤ 0.05. 
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Figure 3. Transgene regulation by amino 
acids. A: Mycoplasma-infected B0AT1-
TMEM27 overexpressing MDCK cells were 
incubated in standard cell culture medium 
(CCAA) or in amino acid-free medium 
complemented with different amounts  (0.5x 
to 8x) of an amino acid mixture 
corresponding to the concentrations found in 
post-absorptive mouse plasma (PAA doses). 
B0AT1 expression was analyzed by Western 
blotting and the intensity of the 
immunoreactive bands was quantified, 
standardized to β-actin and normalized to 
the level measured in 0.5 fold 
complemented medium. B-C: Mycoplasma-
infected B0AT1-TMEM27 overexpressing 
MDCK cells were incubated in a modified 
medium containing the indicated groups (B) 
or single (C) amino acids (NEAA: non 
essential amino acids – Ala, Asn, Asp, Cys, 
Glu, Gln, Gly, Pro and Ser; EAA: essential 
amino acids – Arg, His, Lys, Met and Thr; 
BCAA: branched chain amino acids – Ile, 
Leu and Val; AAA: aromatic amino acids – 
Phe, Trp and Tyr) at 8x their normal plasma 
concentrations whereas the remaining 
amino acids were given at 0.5x their normal 
plasma level. CTR - and + represent cells 
which were treated with all the amino acids 
at 0.5x and 8.0x their plasma level, 
respectively. B0AT1 expression was 
analyzed by Western blotting and intensity 
of the immunoreactive bands was quantified, standardized to β-actin and normalized to 
CTR -. Representative Western blotting images are shown. Data are represented as 
mean ± SEM (n=3). Groups were compared by one-way ANOVA followed by post-test for 
linear trend (A) or Dunnett post-test (B-C); *** p≤ 0.001, ** p≤ 0.01, * p≤ 0.05. 
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Figure 4. Time course and concentration dependence of effect of arginine on 
transgene expression. Mycoplasma-infected B0AT1-TMEM27 overexpressing MDCK cells 
were cultivated in arginine-free DMEM supplemented with 45, 180 or 720 µM arginine for 
the indicated times. A: Real-time PCR quantification of B0AT1 mRNA expression. mRNA 
levels were standardized to β-actin and normalized to time 0. B: Representative Western 
blotting of B0AT1 expression. C: the intensity of B0AT1 immunoreactive bands was 
quantified, standardized to β-actin and normalized to 0 h. Data are represented as mean ± 
SEM (n=3). Groups were compared by two-way ANOVA followed by Bonferroni post-test; 
*** p≤ 0.001, * p≤ 0.05. 
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Figure 5. Time course of arginine metabolism in low and high arginine medium. 
Concentrations of arginine (A) and ornithine (B) were measured in the medium of 
mycoplasma-infected B0AT1-TMEM27 overexpressing MDCK cells treated with 45 µM 
(open bar) or 720 µM (black bar) arginine at the indicated times. Groups were compared by 
one-way ANOVA followed by Dunnett post-test; *** p≤ 0.001, ** p≤ 0.01, * p≤ 0.05 versus 
45 µM arginine; §§§ p≤ 0.001, §§ p≤ 0.01, versus 720 µM arginine. 
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Figure 6. Effect of L-arginine metabolism on transgene expression. A: Schematic 
overview of some mammalian arginine metabolic pathways. ARG: arginase; NO: nitric 
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oxide; NOS: nitric oxide synthase; ODC: ornithine decarboxylase; OTC: ornithine 
transcarbamylase. B-D: Mycoplasma-infected B0AT1-TMEM27 overexpressing MDCK cells 
were cultivated in arginine-free DMEM supplemented with 45 or 720 µM arginine in the 
presence or absence of the indicated concentrations of inhibitors of the following enzymes: 
(B) nitric oxide synthase (NG-nitro-L-arginine methyl ester, L-NAME); (C) ornithine 
decarboxylase (α-difluoromethylornithine, DFMO) and (D) arginase (Nw-Hydroxy-nor-L-
arginine, nor-NOHA). E-F: Mycoplasma-infected B0AT1-TMEM27 overexpressing MDCK 
cells were cultivated in arginine-free DMEM supplemented with 45 µM arginine in the 
absence (negative control, CTR -) or presence of (E) the indicated metabolites or (F) a nitric 
oxide donor (sodium nitroprusside, SNP). Positive control (CTR +) represents cells treated 
with 720 µM arginine. B0AT1 expression was analyzed by Western blotting and intensity of 
the immunoreactive bands was quantified, standardized to β-actin and normalized to 45 µM 
arginine. Representative Western blotting images are shown. Data are represented as 
mean ± SEM (n=3). Groups were compared by one-way ANOVA followed by Dunnett post-
test; *** p≤0.001 ** p≤ 0.01. 
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Figure 7. Effect of arginine on cell signaling. A: Mycoplasma-infected B0AT1-TMEM27 
overexpressing MDCK cells were grown in standard cell culture medium supplemented with 
an inhibitor of histone deacetylation (TSA, 1 µM) for the indicated times. B0AT1 expression 
was analyzed by Western blotting and intensity of the immunoreactive bands was 
quantified, standardized to β-actin and normalized to time 0. Representative Western 
blotting images are shown. Data are represented as mean ± SEM (n=3). Groups were 
compared by two-way ANOVA followed by Bonferroni post-test; *** p≤ 0.001. B-E: 
Mycoplasma-infected B0AT1-TMEM27 overexpressing MDCK cells were incubated with 45 
or 720 µM arginine medium for the indicated times and the whole cell protein extracts were 
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subjected to immunoblotting for total- and phospho-4EBP-1 (B-C) and eIF2α (D-E). 
Representative Western blotting images are shown in B and D. The degree of 4EBP-1 (C) 
and eIF2α (E) phosphorylation was assessed by quantifying the immunoreactive bands of 
the phosphorylated form and normalizing to the total protein in each lane. Data are 
represented as mean ± SEM (n=3). Groups were compared by one-way ANOVA followed 
by Dunnett post-test; ** p≤ 0.01. 
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Figure 8. Effect of arginine on cell number and tight epithelium. Mycoplasma-infected 
MDCK wild type (wt) cells were cultivated in arginine-free DMEM supplemented with 45 or 
720 µM arginine for the indicated times. A: Cell number was estimated based on DAPI-
staining followed by Image J analysis as described in Materials and Methods. B: Trans-
epithelial electrical resistance (TEER) was measured every 24 h using EVOHM device. 
Data in panels A and B are represented as mean ± SEM (n=3). Groups were compared by 
two-way ANOVA followed by Bonferroni post-test; *** p≤ 0.001, ** p≤ 0.01, * = p≤ 0.05. C: 
Immunofluorescence analysis of representative wt MDCK cells with antibodies raised 
against the tight junction protein ZO-1. Scale bar is 10 µm and applies to all panels. 
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Figure S1. Effect of physiological amino acid levels on B0AT1-TMEM27 
overexpressing MDCK cell cultures. After viral transduction, B0AT1-TMEM27 
overexpressing MDCK cells were subcultured on plastic dishes for 10 passages either in 
standard cell culture medium (CCAA) or in physiological medium (PAA). Western blotting 
experiments with antibodies directed against B0AT1 and TMEM27 were performed. The 
intensity of the immunoreactive bands was quantified, standardized to β-actin and 
normalized to CCAA. Data are represented as mean ± SEM (n=3). No significance was 
observed when groups were compared by unpaired two-tailed t-test. 
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Figure S2. Effect of physiological amino acid levels on expression of other 
transgenes. A-B: Mycoplasma-infected MDCK cells overexpressing EGFP (A) or TMEM27 
(B) were cultivated on filters in standard cell culture medium and treated for the indicated 
times with physiological medium. Quantitative RT-PCR analysis was performed and mRNA 
levels were standardized to 18S and normalized to time 0. Data are represented as mean ± 
SEM (n=3). Groups were compared by one-way ANOVA followed by Dunnett post-test; 
*** p≤ 0.001. 
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Tables 
Amino Acid Cell culture medium Physiological medium
Glycine 500 250 
L-Alanine 100 320 
L-Arginine Hydrochloride 398 90 
L-Asparagine 100 50 
L-Aspartic Acid 100 5 
L-Cystine Dihydrochloride 201 30 
L-Glutamic Acid 100 30 
L-Glutamine 5973 660 
L-Histidine Hydrochloride-H
2
O 200 90 
L-Isoleucine 802 60 
L-Leucine 802 120 
L-Lysine Hydrochloride 798 200 
L-Methionine 201 25 
L-Phenylalanine 400 50 
L-Proline 100 160 
L-Serine 500 110 
L-Threonine 798 130 
L-Tryptophan 78 90 
L-Tyrosine 398 60 
L-Valine 803 220 
 
Table 1. Amino acid concentrations (µM) in cell culture and physiological media. 
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Target mRNA Accession number Sequence (5’→3’) 
β-Actin NM_001195845.1 
Sense: CAAGGTTGGGGACTTAGCTG 
Antisense: GAGTAGAGTGAGCATGAGATCCAG
Probe: #97 (Cat no. 04692144001, Roche) 
B
0
AT1 NM_001003841.2 
Sense: GTGTGGACAGGTTCAATAAGGACAT
Antisense: CCACGTGACTTGCCAGAAGAT 
Probe: TCATGATCGGCCACAAGCCCAA 
TMEM27 NM_020665.5  
Sense: CCTCTTCAAAGCGATGGTAGCT 
Antisense: CCCTCTGGGTTACATTGCAAA 
Probe: CCCAACAGAGAAGCAACAGAAATTTCCCA
eGFP YP_002302326.1 
Sense: GTCCGCCCTGAGCAAAGA 
Antisense: TCCAGCAGGACCATGTGATC 
Probe: CCCAACGAGAAGCG
 
Table 2. List of primers and probes used for quantitative real-time PCR. 
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6. DISCUSSION AND OUTLOOK 
 
6.1 Summary of results 
The initial aim of this thesis was to understand the cellular and molecular 
mechanism underlying B0AT1 and TMEM27 interaction. To achieve this goal we 
generated MDCK cells overexpressing B0AT1 and/or TMEM27. Our data showed 
that TMEM27 increases B0AT1 function by upregulating its surface expression. 
In the course of this study, we noticed that B0AT1-TMEM27 protein expression 
strongly decreased following subsequent cell culture passages. This effect was 
specific for the amino acid transporter and its accessory protein as the control cell 
line overexpressing EGFP did show a less significant change in protein expression. 
We speculated that the elevated amino acid concentrations in standard cell culture 
medium exert a negative feedback on the activity and/or expression of B0AT1-
TMEM27, resulting in its downregulation. Unexpectedly, B0AT1-TMEM27 protein 
expression was unaffected by physiological amino acid concentrations in the media. 
Interestingly, mycoplasma infection resulted in a significant increase in transgene 
expression and correlated with the rapid metabolism of L-arginine. However, L-
arginine metabolites were shown to play no role in transgene expression. Instead, 
we observed a rapid increase in eIF2α phosphorylation which suggested that 
activation of the GCN2 pathway may trigger transgene derepression. In addition to 
the transgene regulation, we found that mycoplasma-induced arginine depletion 
dramatically affected MDCK epithelia, resulting in a decrease in cell number and 
trans-epithelial electrical resistance corresponding in a delay in tight junction 
formation. 
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6.2 Outlook 
 
6.2.1 MDCK cell model: inducible or constitutive system? 
 In the first part of this thesis we employed an MDCK cell model overexpressing 
B0AT1 and TMEM27 under the control of an inducible promoter. This system was 
used for a preliminary characterization of the role of TMEM27 in B0AT1 function and 
expression. However, the model showed several disadvantages (uneven co-
expression of the transgenes, loss of transgene expression along cell culture 
passages, endogenous expression of TMEM27 and ACE2) which limited the study 
and the interpretation of the results (see also discussion 4.3.1). To obtain a more 
uniform B0AT1-TMEM27 co-expression, we designed a retroviral IRES-containing 
bicistronic vector which allowed the simultaneous expression of the two proteins 
from the same RNA transcript. MDCK cells transduced with this construct were 
successfully employed later in this study (see manuscript Torrente et al.) and 
showed higher B0AT1-TMEM27 co-expression when compared to the previously 
used inducible system. However, B0AT1-TMEM27 protein expression was still 
rapidly decreased along cell culture passages and could not be rescued by lowering 
amino acid concentrations in the cell culture medium. In summary, B0AT1-TMEM27 
constitutively overexpressing MDCK cells may represent a good model for studying 
the mechanism of B0AT1-TMEM27 interaction. However, the experiments should be 
performed only with low passage cells, as the expression of both transgenes is lost 
during cell culture passages. Furthermore, the endogenous expression of TMEM27 
and ACE2 should be silenced in order to better understand the role of exogenous 
TMEM27 in B0AT1 trafficking to the apical membrane. 
 
6.2.2 Loss of B0AT1-TMEM27 (over)expression in MDCK cells 
 The reason for the loss of B0AT1-TMEM27 protein expression in MDCK cells 
following subsequent cell culture passages remains unclear. The fact that the 
expression of other gene products such as various amino acid antiporters 
(previously studied by Bauch et al., 2002 and 2003) and EGFP (used as control in 
this study) was much more stable suggested a selective downregulation of the 
concentrative amino acid transporter B0AT1-TMEM27. Interestingly, inhibition of the 
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HDACs by TSA resulted in an increase in transgene expression (Fig. 7A from the 
manuscript Torrente et al.). These data suggested that the transgene silencing is 
due to epigenetic modifications rather than transgene loss. To test this hypothesis, 
the effect of HDAC inhibitors in B0AT1-TMEM27 overexpressing MDCK cells 
cultivated at different passages should be assessed. Future studies should also 
investigate the effect of intracellular amino acid concentrations on transgene 
expression. Our data showed that mycoplasma-induced arginine deprivation 
induces transgene derepression. Similarly, previous studies demonstrated that 
deprivation of other essential amino acids, namely Tyr and Cys/Met, leads to 
transgene upregulation (Palmisano et al., 2012). Thus, amino acid concentrations 
play a role in transgene expression regulation. If indeed high intracellular amino acid 
levels induce transgene repression, we could explain the rapid downregulation of 
the concentrative amino acid transporter B0AT1-TMEM27. To address this question, 
experiments with MDCK cells overexpressing B0AT1 mutants which reach the 
plasma membrane but remain inactive (Camargo et al., 2009) should be performed.   
 
6.2.3 What is the role of TMEM27 association to B0AT1? 
 The results presented in this thesis confirmed the importance of TMEM27 for 
B0AT1 surface expression and function. However, the cellular and molecular 
mechanism of their interaction remains still unclear. The physical association of 
TMEM27 to B0AT1 has not been demonstrated in vitro (see discussion 4.3.2). Co-
immunoprecipitation experiments should be repeated with B0AT1-TMEM27 
constitutively overexpressing MDCK cells cultivated at low passage in order to 
guarantee high levels of expression of both transgene proteins. Furthermore, 
different immunoprecipitation conditions (ionic strength of the buffer, detergents, 
etc.) should be tested. It is also to be investigated whether this interaction is direct 
or rather mediated by other proteins, possibly by SNARE's. Similarly to the co-
immunoprecipitation experiments, pulse-chase analysis should also be repeated 
with a more appropriate cell model (see 6.2.1) in order to understand the effect of 
TMEM27 on B0AT1 protein stability (see discussion 4.3.2). Finally, the 
pharmacological block of lysosomal or proteasomal degradation could identify which 
of these pathways might be relevant regarding B0AT1 protein degradation. 
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6.2.4 Renal selective interaction of B0AT1 with TMEM27 
 Even though both TMEM27 and ACE2 are expressed in renal proximal tubules 
(Singer et al., 2009), B0AT1 interacts only with TMEM27 in the kidney. The reason 
for this preferential association remains unclear. One hypothesis is that ACE2 has 
another partner protein in proximal tubule cells. This association could prevent 
ACE2 from interacting with B0AT1, as well as with other SLC6 amino acid 
transporters. Another possibility is that ACE2 requires a specific protein for its 
interaction with the SLC6 amino acid transporters. This protein might be expressed 
in the intestine and absent in the kidney. One strategy to determine putative ACE2 
binding proteins could be to isolate complexes from renal and intestinal lysates 
using anti-ACE2 antibodies, followed by mass spectrometry analysis. The identified 
binding partners could then be subsequently verified by co-immunoprecipitation 
experiments. Recent studies showed that indeed in the small intestine ACE2 forms 
a complex with other proteins including B0AT1 (Fairweather et al., 2012) 
 
6.2.5 Is B0AT1 regulated by amino acids in vivo? 
 The initial hypothesis that B0AT1 expression could be regulated by amino acids 
in vitro was not confirmed in MDCK cells. The subsequently observed rapid 
upregulation of B0AT1 mRNA and protein expression (within few days) upon culture 
in low amino acid containing medium was shown to be caused by mycoplasma-
induced arginine depletion and affected also other tested transgenes. The regulation 
of amino acid transporter by amino acids remains an interesting and physiologically 
very relevant question. Indeed, protein diets have been shown to affect the 
expression of intestinal peptide transporters (i.e. PepT1) and amino acid 
transporters (i.e. EAAC1/SLC1A1) in vivo (Erickson et al., 1995; Shiraga et al., 
1999). Furthermore, expression of the glucose transporter SGLT1 and PepT1 has 
been shown to be submitted to circadian regulation and food entrainment (Pan et 
al., 2004;  Qandeel et al. 2009). Future studies should characterize the short- and 
long-term effect of protein diets on renal and intestinal B0AT1 expression and 
function in in vivo models. Circadian regulation should also be taken into account 
when investigating the regulation of this amino acid transporter. 
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6.2.6 Transgene expression regulation by GCN2 pathway 
  The present study showed that mycoplasma-induced arginine deprivation 
triggers the increase in eIF2α phosphorylation in MDCK cells. Therefore, we 
suggested that transgene regulation is mediated by the activation of the GCN2 
pathway. The GCN2 kinase is activated upon any amino acid limitation (Wek et al., 
1995). It would be interesting to determine whether single amino acid deprivation 
increases transgene expression in mycoplasma-free MDCK cells. Furthermore, the 
mechanism regulating transgene transcription in mycoplasma-infected MDCK cells 
should be further investigated. 
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